

1 ATAAAGGCTAGCCTGAGGAGCTGCTGGACAGTCCACTTTTTCGAGAGTGACTCCC 60

Db 1 ATACGGCTAGCCTGAGAGCTGCTGCGACAGTCCACTTCTTTTCGAGAGTACTCCC 60  
Qy 61 GTTGTCCCAAGGCTTCCAGAGGAACTGTGCGGCTGAGGACCGGCGCTGAGATT 120  
Db 61 GTTGTCCCAAGGCTTCCAGAGGAACTGTGCGGCTGAGGACCGGCGCTGAGATT 120  
Qy 121 CCGGGCTCCGGAAGAACCGAGCTCTTCTGCGGATCCAGTGTTCGTTCCAGCCCCCA 180  
Db 121 CCGGGCTCCGGAAGAACCGAGCTCTTCTGCGGATCCAGTGTTCGTTCCAGCCCCCA 180  
Qy 181 TCTCAGAGCCGAGCCGACAGAGAGGAGAACCGC 215  
Db 181 TCTCAGAGCCGAGCCGACAGAGAGGAGAACCGC 215

RESULT 2  
BD273754 215 bp RNA linear PAT 17-JUL-2003  
LOCUS BD273754  
DEFINITION Expression.  
ACCESSION BD273754  
VERSION BD273754.1 GI:33083522  
KEYWORDS JP 2002537843-A/2.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE Coste,H.J. and Ellis,J.H.  
AUTHORS Coste,H.J. and Ellis,J.H.  
TITLE Expression  
JOURNAL Patent: JP 2002537843-A 2 12-NOV-2002;  
GLAXO GROUP LTD  
COMMENT OS Homo sapiens (human)  
PN JP 2002537843-A/2  
PD 12-NOV-2002  
PF 09-MAR-2000 JP 200603406  
PR 11-MAR-1999 GB 9905498.3  
PI HERVE JEAN-CLEMENT COSTE,JONATHAN HENRY ELLIS PC  
C12N15/09,A61K38/44,A61K39/00,A61K48/00,C07K14/46,C12N5/10, PC  
C12P21/02,  
PC C12N15/00,C12N5/00,A61K37/50  
CC Expression  
FH Key  
FT source  
FT Location/Qualifiers  
1..215 /organism='Homo sapiens (human)'.  
1..215 /organism='Homo sapiens'  
/mol\_type='genomic RNA'  
/db\_xref='taxon:9606'

ORIGIN  
Query Match 100.0%; Score 215; DB 6; Length 215;  
Best Local Similarity 100.0%; Pred. No. 1,3e-46;  
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

AX036038 215 bp DNA linear PAT 15-NOV-2000  
LOCUS AX036038  
DEFINITION Sequence 1 from Patent WO0053785.  
ACCESSION AX036038  
VERSION AX036038.1 GI:11191577  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE Coste,H.J. and Ellis,J.H.  
AUTHORS Coste,H.J. and Ellis,J.H.  
TITLE Expression  
JOURNAL Patent: WO 0053785-A 1 14-SEP-2000;  
COSTE HERVE JEAN CLEMENT (FR) ; GLAXO GROUP LTD (GB) ; ELLIS  
JONATHAN HENRY (GB)  
FEATURES  
source 1..215  
Location/Qualifiers  
1..215 /organism='Homo sapiens'  
/mol\_type='unassigned DNA'  
/db\_xref='taxon:9606'

ORIGIN  
Query Match 100.0%; Score 215; DB 6; Length 215;  
Best Local Similarity 100.0%; Pred. No. 1,3e-46;  
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ATACGGCTAGCCTGAGAGCTGCTGCGACAGTCCACTTCTTTTCGAGAGTACTCCC 60  
Db 1 ATACGGCTAGCCTGAGAGCTGCTGCGACAGTCCACTTCTTTTCGAGAGTACTCCC 60  
Qy 61 GTTGTCCCAAGGCTTCCAGAGGAACTGTGCGGCTGAGGACCGGCGCTGAGATT 120  
Db 61 GTTGTCCCAAGGCTTCCAGAGGAACTGTGCGGCTGAGGACCGGCGCTGAGATT 120  
Qy 121 CCGGGCTCCGGAAGAACCGAGCTCTTCTGCGGATCCAGTGTTCGTTCCAGCCCCCA 180  
Db 121 CCGGGCTCCGGAAGAACCGAGCTCTTCTGCGGATCCAGTGTTCGTTCCAGCCCCCA 180  
Qy 181 TCTCAGAGCCGAGCCGACAGAGAGGAGAACCGC 215  
Db 181 TCTCAGAGCCGAGCCGACAGAGAGGAGAACCGC 215

RESULT 4  
AX036039 215 bp RNA linear PAT 15-NOV-2000  
LOCUS AX036039  
DEFINITION Sequence 2 from Patent WO0053785.  
ACCESSION AX036039  
VERSION AX036039.1 GI:11191578  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE Coste,H.J. and Ellis,J.H.  
AUTHORS Coste,H.J. and Ellis,J.H.  
TITLE Expression  
JOURNAL Patent: WO 0053785-A 2 14-SEP-2000;  
COSTE HERVE JEAN CLEMENT (FR) ; GLAXO GROUP LTD (GB) ; ELLIS  
JONATHAN HENRY (GB)  
FEATURES  
source 1..215  
Location/Qualifiers  
1..215 /organism='Homo sapiens'  
/mol\_type='unassigned RNA'  
/db\_xref='taxon:9606'

ORIGIN  
Query Match 100.0%; Score 215; DB 6; Length 215;  
Best Local Similarity 100.0%; Pred. No. 1,3e-46;  
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ATACGGCTAGCCTGAGAGCTGCTGCGACAGTCCACTTCTTTTCGAGAGTACTCCC 60

Db	1	ATTAACGGCTACCTGAGAGAGCTGCTGCGACAGTCCACTACTCTTTTTCAGAGTGA	CTCCC	60
Qy	61	GTGTGCCAAGGCTTCCAGAGCGAACTGTGTGCGGCTGACAGCAACCGGCGGTCGAGTTT		120
Db	61	GTGTGCCAAGGCTTCCAGAGCGAACTGTGTGCGGCTGACAGCAACCGGCGGTCGAGTTT		120
Qy	121	CCGGCGTCCGGAAGAACCGAGCTCTTCTTCGCGGATCCAGTGTTCGTTTCCAGCCCCAA		180
Db	121	CCGGCGTCCGGAAGAACCGAGCTCTTCTTCGCGGATCCAGTGTTCGTTTCCAGCCCCAA		180
Qy	181	TCTCAGAGCCGAGCCGACAGAGACGAGGAAACCGC		215
Db	181	TCTCAGAGCCGAGCCGACAGAGACGAGGAAACCGC		215
RESULT 5				
AR084816				
LOCUS		533 bp	DNA	linear
DEFINITION		Sequence 2 from patent US 5981224.		PAT 01-SEP-2000
AR084816				
ACCESSION				
VERSION		AR084816.1	GI:10011587	
KEYWORDS				
SOURCE		Unknown.		
ORGANISM		Unknown.		
REFERENCE		1 (bases 1 to 533)		
AUTHORS		Kowalski,J., Gilbert,S. and Zamb,T.J.		
TITLE		Bovine heat shock promoter and uses thereof		
JOURNAL		Patent: US 5981224-A 2 09-NOV-1999;		
FEATURES		location/Qualifiers		
SOURCE		1..533		
ORIGIN		/organism="unknown"		
		/mol_type="unassigned DNA"		
Query Match		100.0%; Score 215; DB 6; Length 533;		
Best Local Similarity		100.0%; Pred. No. 1.2e-46;		
Matches 215; Conservative		0; Mismatches 0; Indels 0; Gaps 0;		
Qy	1	ATTAACGGCTACCTGAGAGAGCTGTGTGCGACAGTCCACTACTCTTTTTCAGAGTGA	CTCCC	60
Db	235	ATTAACGGCTACCTGAGAGAGCTGTGTGCGACAGTCCACTACTCTTTTTCAGAGTGA	CTCCC	294
Qy	61	GTGTGCCAAGGCTTCCAGAGCGAACTGTGTGCGGCTGACAGCAACCGGCGGTCGAGTTT		120
Db	295	GTGTGCCAAGGCTTCCAGAGCGAACTGTGTGCGGCTGACAGCAACCGGCGGTCGAGTTT		354
Qy	121	CCGGCGTCCGGAAGAACCGAGCTCTTCTTCGCGGATCCAGTGTTCGTTTCCAGCCCCAA		180
Db	355	CCGGCGTCCGGAAGAACCGAGCTCTTCTTCGCGGATCCAGTGTTCGTTTCCAGCCCCAA		414
Qy	181	TCTCAGAGCCGAGCCGACAGAGACGAGGAAACCGC		215
Db	415	TCTCAGAGCCGAGCCGACAGAGACGAGGAAACCGC		449
RESULT 6				
LOCUS		121401	533 bp	DNA
DEFINITION		Sequence 2 from patent US 5521084.		linear
AR084816				PAT 07-OCT-1996
ACCESSION		121401		
VERSION		121401.1	GI:1601755	
KEYWORDS				
SOURCE		Unknown.		
ORGANISM		Unknown.		
REFERENCE		1 (bases 1 to 533)		
AUTHORS		Kowalski,J., Gilbert,S. and Zamb,T.J.		
TITLE		Bovine heat shock promoter and uses thereof		
JOURNAL		Patent: US 5521084-A 2 28-MAY-1996;		
FEATURES		location/Qualifiers		
SOURCE		1..533		

ORIGIN	/organism="unknown" /mol_type="unassigned DNA"			
Query Match	100.0%;	Score 215;	DB 6;	Length 533;
Best Local Similarity	100.0%;	Pred. No. 1.2e-46;		
Matches	215;	Conservative 0;	Mismatches 0;	Indels 0; Gaps 0;
QY	1 ATAACGGCTAGCTCGAGAGCTGCTGGGACAGTTCACCTACTCTTTTGGAGAGTACATCCC 60			
Db	235 ATAAACGGCTAGCTCGAGAGCTGCTGGGACAGTTCACCTACTCTTTTGGAGAGTACATCCC 294			
QY	61 GTTGTCCCAAGGCTTCCCAAGAGCACTGTGCGGCTGCAGAGCAACGGCGGTGAGTTT 120			
Db	295 GTTGTCCCAAGGCTTCCCAAGAGCACTGTGCGGCTGCAGAGCAACGGCGGTGAGTTT 354			
QY	121 CCGCGCTTCGGAGAGAGCCGAGCTTCTTCGGGATCCAGTGTTCGGTTCCAGCCCCCA 180			
Db	355 CCGCGCTTCGGAGAGAGCCGAGCTTCTTCGGGATCCAGTGTTCGGTTCCAGCCCCCA 414			
QY	181 TCTCAGAGCCGAGCCGACAGAGAGCAGGAAACCCG 215			
Db	415 TCTCAGAGCCGAGCCGACAGAGAGCAGGAAACCCG 449			
RESULT 7				
195741	195741	533 bp	DNA	linear PAT 01-DEC-1998
LOCUS				
DEFINITION	Sequence 2 from patent US 5733745.			
ACCESSION	195741			
VERSION	195741.1 GI:3940211			
KEYWORDS				
SOURCE	Unknown.			
ORGANISM	Unknown.			
REFERENCE	1 (bases 1 to 533)			
AUTHORS	Kowalewski, J., Gilbert, S. and Zamb, T. J.			
TITLE	Bovine heat shock promoter and uses thereof			
JOURNAL	Patent: US 5733745-A 2 31-MAR-1998;			
FEATURES	Location/Qualifiers			
source	1..533			
	/organism="unknown"			
	/mol_type="unassigned DNA"			
ORIGIN				
Query Match	100.0%;	Score 215;	DB 6;	Length 533;
Best Local Similarity	100.0%;	Pred. No. 1.2e-46;		
Matches	215;	Conservative 0;	Mismatches 0;	Indels 0; Gaps 0;
QY	1 ATAAACGGCTAGCTCGAGAGCTGCTGGGACAGTTCACCTACTCTTTTGGAGAGTACATCCC 60			
Db	235 ATAAACGGCTAGCTCGAGAGCTGCTGGGACAGTTCACCTACTCTTTTGGAGAGTACATCCC 294			
QY	61 GTTGTCCCAAGGCTTCCCAAGAGCACTGTGCGGCTGCAGAGCAACGGCGGTGAGTTT 120			
Db	295 GTTGTCCCAAGGCTTCCCAAGAGCACTGTGCGGCTGCAGAGCAACGGCGGTGAGTTT 354			
QY	121 CCGCGCTTCGGAGAGAGCCGAGCTTCTTCGGGATCCAGTGTTCGGTTCCAGCCCCCA 180			
Db	355 CCGCGCTTCGGAGAGAGCCGAGCTTCTTCGGGATCCAGTGTTCGGTTCCAGCCCCCA 414			
QY	181 TCTCAGAGCCGAGCCGACAGAGAGCAGGAAACCCG 215			
Db	415 TCTCAGAGCCGAGCCGACAGAGAGCAGGAAACCCG 449			
RESULT 8				
E12384	E12384	2465 bp	DNA	linear PAT 27-APR-1998
LOCUS				
DEFINITION	Human cDNA encoding HSP70.			
ACCESSION	E12384			
VERSION	E12384.1 GI:3251217			
KEYWORDS	JP 1996322577-A/1.			

SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
TITLE 1 (bases 1 to 2465)  
Demura,H., Nomura,K., Shimizu,S., Raaij,T.H. and Hisekawa,Y.  
TRANSCRIPTIONAL ABNORMALITY OF INTRACELLULAR HSP70/MRNA UNDER  
SUSTAINED STRESS LOAD CONTAINING HUMAN ACUTENESS AND CHRONICITY AND  
ITS APPLICATION (APPLICATION OF BOTH TRANSCRIPTIONAL EXPRESSION OF  
NEW HUMAN INTRACELLULAR HSP70/MRNA AND TRANSCRIPTIONAL ABNORMALITY  
OF HSP70 mRNA)  
Patent: JP 1996322577-A 1 10-DEC-1996;  
JOURNAL HOKEN KAGAKU KENKYUSHO:KK  
COMMENT OS Homo sapiens (human)  
PN JP 1996322577-A/1  
PD 10-DEC-1996  
PF 01-JUN-1995 JP 199518581  
PI DEMURA HIROSHI, NOMURA KAORU, SHIMIZU SHOICHI, PI RAAIJ  
TABURIZU HANKINZU  
PI HISAKAWA YOSHIZO  
PC C12N15/09,C12P21/02,C12Q1/68;  
CC strandedness: Double;  
CC topology: Linear;  
FH Key location/Qualifiers  
FT source 1..2465  
FT /organism='Homo sapiens'  
FT /tissue type='lymphocyte'  
FT CDS 263..2185  
FT /product='HSP70'  
FT mutation join(1..143,306,,2465)  
FT /note= alternative splicing caused by stress'.  
FEATURES source  
1..2465  
location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
ORIGIN  
Query Match 100.0%; Score 215; DB 6; Length 2465;  
Best Local Similarity 100.0%; Pred. No. 1.1e-46;  
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 ATAAAGGCTAGAGCTTGGAGAGCTCTCCGACAGTCCATACCTTTTTCAGAGTACTCCC 60  
DB 48 ATAAAGGCTAGAGCTTGGAGAGCTCTCCGACAGTCCATACCTTTTTCAGAGTACTCCC 107  
QY 61 GTTGTCCCAAGGCTTCCAGAGGAACTGTGGCGGTGAGGACCGGGCGCTCGAGTTT 120  
DB 108 GTTGTCCCAAGGCTTCCAGAGGAACTGTGGCGGTGAGGACCGGGCGCTCGAGTTT 167  
QY 121 CCGGCGTCCGGAAGACCGAGCTTTCTCGCGGATCCAGTGTTCGATCCAGCCCCCA 180  
DB 168 CCGGCGTCCGGAAGACCGAGCTTTCTCGCGGATCCAGTGTTCGATCCAGCCCCCA 227  
QY 181 TCTCAGAGCCGAGCCGACAGAGAGGAGGAAACCGC 215  
DB 228 TCTCAGAGCCGAGCCGACAGAGAGGAGGAAACCGC 262  
RESULT 9  
LOCUS CQ812310 2691 bp DNA linear PAT 24-MAY-2004  
DEFINITION Sequence 62 from Patent WO2004038020.  
ACCESSION CQ812310  
VERSION CQ812310.1 GI:47601930  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
TITLE 1  
Witlig,R., Pousetka,A., Mollenhauer,J. and Schadenorrf,D.

TITLE Target genes for the diagnosis and treatment of cancer  
JOURNAL Patent: WO 2004038020-A 62 06-MAY-2004;  
Deutsches Krebsforschungszentrum Stiftung des oeffentlichen n Rechts  
(DE)  
FEATURES source location/Qualifiers  
1..2691  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
misc\_feature 1..2691  
/note="M11717"  
ORIGIN  
Query Match 100.0%; Score 215; DB 6; Length 2691;  
Best Local Similarity 100.0%; Pred. No. 1.1e-46;  
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 ATAAAGGCTAGAGCTTGGAGAGCTCTCCGACAGTCCATACCTTTTTCAGAGTACTCCC 60  
DB 274 ATAAAGGCTAGAGCTTGGAGAGCTCTCCGACAGTCCATACCTTTTTCAGAGTACTCCC 333  
QY 61 GTTGTCCCAAGGCTTCCAGAGGAACTGTGGCGGTGAGGACCGGGCGCTCGAGTTT 120  
DB 334 GTTGTCCCAAGGCTTCCAGAGGAACTGTGGCGGTGAGGACCGGGCGCTCGAGTTT 393  
QY 121 CCGGCGTCCGGAAGACCGAGCTTTCTCGCGGATCCAGTGTTCGATCCAGCCCCCA 180  
DB 394 CCGGCGTCCGGAAGACCGAGCTTTCTCGCGGATCCAGTGTTCGATCCAGCCCCCA 453  
RESULT 10  
LOCUS CQ818823 2691 bp DNA linear PAT 07-JUN-2004  
DEFINITION Sequence 6 from Patent WO2004039412.  
ACCESSION CQ818823  
VERSION CQ818823.1 GI:48427426  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
TITLE 1  
Doiron,B., Pownall,S., Cheung,A. and Hsu,E.  
Compositions for cancer treatment  
Patent: WO 2004039412-A 6 13-MAY-2004;  
JOURNAL Engine, Inc. (CA)  
FEATURES source location/Qualifiers  
1..2691  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
ORIGIN  
Query Match 100.0%; Score 215; DB 6; Length 2691;  
Best Local Similarity 100.0%; Pred. No. 1.1e-46;  
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 ATAAAGGCTAGAGCTTGGAGAGCTCTCCGACAGTCCATACCTTTTTCAGAGTACTCCC 60  
DB 274 ATAAAGGCTAGAGCTTGGAGAGCTCTCCGACAGTCCATACCTTTTTCAGAGTACTCCC 333  
QY 61 GTTGTCCCAAGGCTTCCAGAGGAACTGTGGCGGTGAGGACCGGGCGCTCGAGTTT 120  
DB 334 GTTGTCCCAAGGCTTCCAGAGGAACTGTGGCGGTGAGGACCGGGCGCTCGAGTTT 393  
QY 121 CCGGCGTCCGGAAGACCGAGCTTTCTCGCGGATCCAGTGTTCGATCCAGCCCCCA 180  
DB 394 CCGGCGTCCGGAAGACCGAGCTTTCTCGCGGATCCAGTGTTCGATCCAGCCCCCA 453

Qy 181 TCTCAGAGCCGAGCCGACAGAGAGGAGGAAACCGC 215  
Db 454 TCTCAGAGCCGAGCCGACAGAGAGGAGGAAACCGC 488

RESULT 11  
AR62810  
LOCUS AR62810 2691 bp DNA linear PAT 29-JAN-2003  
DEFINITION Sequence 1 from patent US 6331388.  
ACCESSION AR62810  
VERSION AR62810.1 GI:28074512  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 2691)  
AUTHORS Malkovsky,M. and Wells,A.D.  
TITLE Immune response enhancer  
JOURNAL Patent: US 6331388-A 1 18-DEC-2001;  
FEATURES Location/Qualifiers  
source 1..2691  
/organism="unknown"  
/mol\_type="genomic DNA"

ORIGIN  
Query Match 100.0%; Score 215; DB 6; Length 2691;  
Best Local Similarity 100.0%; Pred. No. 1,1e-46;  
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ATPACGGCTAGCCTGAGAGCTGCTGCGACATGCTACTTTCGAGAGTACTCC 60  
Db 274 ATPACGGCTAGCCTGAGAGCTGCTGCGACATGCTACTTTCGAGAGTACTCC 333

Qy 61 GTTGTCCCAAGCTTCCGAGGAACTGTGGGCTGAGGACCGGCGCTCGAGTTT 120  
Db 334 GTTGTCCCAAGCTTCCGAGGAACTGTGGGCTGAGGACCGGCGCTCGAGTTT 393

Qy 121 CCGGCGTCCGGAAGAGACCGAGCTTCTCGCGGATCCAGTGTTCGTTTCCAGCCCAA 180  
Db 394 CCGGCGTCCGGAAGAGACCGAGCTTCTCGCGGATCCAGTGTTCGTTTCCAGCCCAA 453

Qy 181 TCTCAGAGCCGAGCCGACAGAGAGGAGAACCGC 215  
Db 454 TCTCAGAGCCGAGCCGACAGAGAGGAGAACCGC 488

RESULT 12  
HUMHSP70D 2691 bp DNA linear PRI 08-NOV-1994  
LOCUS HUMHSP70D  
DEFINITION Human heat shock protein (hsp 70) gene, complete cds.  
ACCESSION M11717 M15432  
VERSION M11717.1 GI:184416  
KEYWORDS HSP70 gene; heat shock protein.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1 (bases 1 to 2691)  
AUTHORS Hunt,C. and Morimoto,R.I.  
TITLE Conserved features of eukaryotic hsp70 genes revealed by comparison with the nucleotide sequence of human hsp70  
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 82 (19), 6455-6459 (1985)  
MEDLINE 86016721  
PUBMED 3931075  
REFERENCE 2 (bases 94 to 293)  
AUTHORS Morjan,W.D., Williams,G.T., Morimoto,R.I., Greene,J., Kingston,R.E. and Tjian,R.  
TITLE Two transcriptional activators, CCAAT-box-binding transcription factor and heat shock transcription factor, interact with a human hsp70 gene promoter  
JOURNAL Mol. Cell. Biol. 7 (3), 1129-1138 (1987)  
MEDLINE 87172780  
PUBMED 3561411

COMMENT Original source text: Homo sapiens DNA.  
[2] revises [1]. Sequence revised July 30, 1992.  
FEATURES Location/Qualifiers  
source 1..2691  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
/map="6p21.3"  
274..2691  
/product="70 kda hsp mRNA"  
489..2411  
/gene="HSP70"  
/note="HSP70"  
/gene="HSP70"  
/note="70 kda"  
/codon\_start=1  
/product="heat shock protein"  
/protein\_id="AAA52697.1"  
/db\_xref="GI:386785"  
/db\_xref="GDB:G00-120-058"  
/translation="MAKAAVGIDIGTTCYCVGFPHGKVELIANDGGRTPSYAF  
TDERLIGDAKNQVAILNPQTVTPAKRLIGKRPDPVQVSMKMPFVINDGKPK  
VQVSYKGETKATFPEISWVLTAKKEIAEALGIPVNAVITVPAFVDSORATKD  
AGVIALGNVARIINEPTAALAYGLDRCKGRNVLIIDLAGGTFDVSILITDGLFE  
VKATAGDTILGSEDFDNRVNHVEEFKXKAKDLSQNRKAVRLRTACERAKRTLS  
STQASLEIDSLPEGIDFTYSIRAFBELCSLPFSTLEPVEKALADAKLDAQIIDL  
VIVGSTRIPKVKLIDPFNGRDLNKSINPEAVGAAVOAAILMDGKSRNVODL  
LIDVAPLSIGLETAGVNTALIKRSTIPTKQTQFTTYSNDQPVLIQVYGERAMT  
KNNLIRFELSGITPPAPGVPIEYTFDIDANGILNVATIDKSTGKANKITINDGR  
LSKEIIRNVQSAEKAEVQRRVSAKNALSYAFNMKSAVDEGKXKRISEADK  
KVLDKCEVISMIDANTLAEKDEFEHKKLEIQVCPNPIISGLYQAGAGPGRGFGAQ  
GPKGSGSGPTIEVD"

ORIGIN  
Query Match 100.0%; Score 215; DB 9; Length 2691;  
Best Local Similarity 100.0%; Pred. No. 1,1e-46;  
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ATPACGGCTAGCCTGAGAGCTGCTGCGACATGCTACTTTCGAGAGTACTCC 60  
Db 274 ATPACGGCTAGCCTGAGAGCTGCTGCGACATGCTACTTTCGAGAGTACTCC 333

Qy 61 GTTGTCCCAAGCTTCCGAGGAACTGTGGGCTGAGGACCGGCGCTCGAGTTT 120  
Db 334 GTTGTCCCAAGCTTCCGAGGAACTGTGGGCTGAGGACCGGCGCTCGAGTTT 393

Qy 121 CCGGCGTCCGGAAGAGACCGAGCTTCTCGCGGATCCAGTGTTCGTTTCCAGCCCAA 180  
Db 394 CCGGCGTCCGGAAGAGACCGAGCTTCTCGCGGATCCAGTGTTCGTTTCCAGCCCAA 453

Qy 181 TCTCAGAGCCGAGCCGACAGAGAGGAGAACCGC 215  
Db 454 TCTCAGAGCCGAGCCGACAGAGAGGAGAACCGC 488

RESULT 13  
AB018045 4360 bp DNA linear PRI 14-APR-2000  
LOCUS AB018045  
DEFINITION Homo sapiens HSP70-1 gene for heat shock protein 72, spliced variant, partial cds.  
ACCESSION AB018045  
VERSION AB018045.1 GI:4691417  
KEYWORDS HSP70-1; heat shock protein 72; HSP70-Hom; alternative splicing.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1 (sites)  
AUTHORS Shimizu,S., Nomura,K., Ujihara,M. and Demura,H.  
TITLE An additional exon of stress-inducible heat shock protein 70 gene (HSP70-1)  
JOURNAL Biochem. Res. Commun. 257 (1), 193-198 (1999)  
MEDLINE 99194576

PUBMED 10092532  
REFERENCE 2 (bases 1 to 4360)  
AUTHORS Nomura, K. and Shimizu, S.  
TITLE Direct Submission  
JOURNAL Submitted (27-SEP-1998) Kaoru Nomura, Tokyo Women's Medical University, Department of Medicine 2, 8-1 Kawadacho, Shinjyuku-ku, Tokyo 162-8666, Japan (E-mail: nomura@parkcity.ne.jp, Tel: 81-3-3353-8111 (ex. 39223), Fax: 81-3-3357-6475)  
COMMENT Sequence updated (26-Oct-1998).  
FEATURES  
source 1..4360  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
/chromosome="6"  
/map="6p21.3"  
/complement(1..196)  
/gene="HSP70-Hom"  
complement(1..196)  
/gene="HSP70-Hom"  
2323..4360  
/gene="HSP70-1"  
2323..2679  
/gene="HSP70-1"  
/note="alternative splicing"  
/number=1  
join(2632..2679,3955..4360)  
/gene="HSP70-1"  
/note="spliced variant"  
/codon\_start=1  
/product="heat shock protein 72"  
/protein\_id="BAA77235.1"  
/db\_xref="GI:4691418"  
/translation="MKHMPFOYINDDKPKVOVSYKETKAFYPEEISSMVLTKKKEI  
AEAYGYPTNAVITVPAYFNDSORQATDAGIAGLVLRILNEPTAAIAVGLDRT  
GEGRNVLFDGCGTFPVSILTIDGIREVATADPTHLGSEDPDNRQ"  
3443..3954  
/gene="HSP70-1"  
/note="alternative splicing  
transcription usually starts from exon 2"  
/number=2  
3955..4360  
/gene="HSP70-1"  
/note="alternative splicing"  
/number=3  
ORIGIN  
Query Match 100.0%; Score 215; DB 9; Length 4360;  
Best Local Similarity 100.0%; Pred. No. 1,1e-46;  
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 ATAAAGCGCTAGCTGAGAGCTGCTCGACAGTCCACTACCTTTTCGAGAGTACTCCC 60  
DB 3434 ATAAAGCGCTAGCTGAGAGCTGCTCGACAGTCCACTACCTTTTCGAGAGTACTCCC 3493  
QY 61 GTTGTCCCAAGGCTTCCAGAGGAACTGTGGCGCTGACGACCGGCGCGTCAAGTT 120  
DB 3494 GTTGTCCCAAGGCTTCCAGAGGAACTGTGGCGCTGACGACCGGCGCGTCAAGTT 3553  
QY 121 CCGGCGCTCCGGAAGAACCGAGCTTCTCGCGGATCCAGTGTTCGTTTCCAGCCCCCA 180  
DB 3554 CCGGCGCTCCGGAAGAACCGAGCTTCTCGCGGATCCAGTGTTCGTTTCCAGCCCCCA 3613  
QY 181 TCTCAGAGCCGAGCCGACAGAGAGGAGGAAACCGC 215  
DB 3614 TCTCAGAGCCGAGCCGACAGAGAGGAGGAAACCGC 3648  
RESULT 14  
S52686 488 bp DNA linear PRI 08-MAY-1993  
LOCUS S52686  
DEFINITION HLA class III polymorphic region: HSP70-1-heat shock protein 70 {5'  
region} [human, Pef, WT49, WT51, Genomic, 488 nt].

ACCESSION S52686  
VERSION S52686.1 GI:263578  
KEYWORDS  
SOURCE  
ORGANISM Homo sapiens (human)  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1 (bases 1 to 488)  
AUTHORS Casacio, I., Sorrentino, R. and Tosi, R.  
TITLE Strong genetic association between HLA-DR3 and a polymorphic  
variation in the regulatory region of the HSP70-1 gene  
Immunogenetics 37 (3), 177-182 (1993)  
JOURNAL 9331289  
MEDLINE 8420825  
PUBMED  
REMARK  
COMMENT  
FEATURES  
source 1..488  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
1..488  
/gene="HSP70-1"  
/note="heat shock protein 70"  
ORIGIN  
Query Match 99.8%; Score 214.6; DB 9; Length 488;  
Best Local Similarity 99.5%; Pred. No. 1,1e-46;  
Matches 214; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 1 ATAAAGCGCTAGCTGAGAGCTGCTCGACAGTCCACTACCTTTTCGAGAGTACTCCC 60  
DB 274 ATAAAGCGCTAGCTGAGAGCTGCTCGACAGTCCACTACCTTTTCGAGAGTACTCCC 333  
QY 61 GTTGTCCCAAGGCTTCCAGAGGAACTGTGGCGCTGACGACCGGCGCGTCAAGTT 120  
DB 334 GTTGTCCCAAGGCTTCCAGAGGAACTGTGGCGCTGACGACCGGCGCGTCAAGTT 393  
QY 121 CCGGCGCTCCGGAAGAACCGAGCTTCTCGCGGATCCAGTGTTCGTTTCCAGCCCCCA 180  
DB 394 CCGGCGCTCCGGAAGAACCGAGCTTCTCGCGGATCCAGTGTTCGTTTCCAGCCCCCA 453  
QY 181 TCTCAGAGCCGAGCCGACAGAGAGGAGGAAACCGC 215  
DB 454 TCTCAGAGCCGAGCCGACAGAGAGGAGGAAACCGC 488  
RESULT 15  
CO806661 5387 bp DNA linear PAT 10-MAY-2004  
LOCUS CO806661  
DEFINITION Sequence 111 from Patent WO2004035803.  
ACCESSION CO806661  
VERSION CO806661.1 GI:47112043  
KEYWORDS  
SOURCE  
ORGANISM Homo sapiens (human)  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1  
AUTHORS Foekens, J., Harbeck, N., Koenig, T., Maier, S., Martens, J., Model, F.,  
Nimmrich, I., Rujan, T., Schmitt, A., Schmitt, M., Look, M.P. and  
Marx, A.  
TITLE Method and nucleic acids for the improved treatment of breast cell  
proliferative disorders  
Patent: WO 2004035803-A 111 29-APR-2004;  
JOURNAL Epigenomics AG (DE)  
FEATURES  
source 1..5387  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 99.5%; Score 214; DB 6; Length 5387;  
 Best Local Similarity 100.0%; Pred. No. 2e-46;  
 Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	ATAACGGCTAGCCTGAGAGCTGCTGCGACAGTCCACTACTTTTCGAGAGTGACTCCC	60
DB	1982	ATAACGGCTAGCCTGAGAGCTGCTGCGACAGTCCACTACTTTTCGAGAGTGACTCCC	2041
QY	61	GTTGTCCCAAGGCTTCCAGAGCGAACCTGTGCGGCTGAGGACCCGGCGTCCAGTTT	120
DB	2042	GTTGTCCCAAGGCTTCCAGAGCGAACCTGTGCGGCTGAGGACCCGGCGTCCAGTTT	2101
QY	121	CCGGCGTCCGGAAGACCGAGCTCTTCTCGCGATCCAGTGTTCGTTCCAGCCCCCA	180
DB	2102	CCGGCGTCCGGAAGACCGAGCTCTTCTCGCGATCCAGTGTTCGTTCCAGCCCCCA	2161
QY	181	TCTCAGAGCCGAGCCGACAGAGACAGGGAACCG	214
DB	2162	TCTCAGAGCCGAGCCGACAGAGACAGGGAACCG	2195

Search completed: February 11, 2005, 08:35:10  
 Job time : 1055 secs

This Page Blank (uspic)



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 11, 2005, 06:52:38 ; Search time 221 Seconds  
(without alignments)  
5759.024 Million cell updates/sec

Title: US-09-936-506-1

Perfect score: 215  
Sequence: 1 ataacgcgtacgtcgtgagag.....gacagagacgaggaaccgc 215

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 1.0

Searched: 4390206 seqs, 2959870667 residues

Total number of hits satisfying chosen parameters: 8780412

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : N\_Geneseq\_1Dec04:\*  
1: geneeqn19808:\*  
2: geneeqn19908:\*  
3: geneeqn20008:\*  
4: geneeqn2001as:\*  
5: geneeqn2001bs:\*  
6: geneeqn2002as:\*  
7: geneeqn2002bs:\*  
8: geneeqn2003as:\*  
9: geneeqn2003bs:\*  
10: geneeqn2003cs:\*  
11: geneeqn2003ds:\*  
12: geneeqn2004as:\*  
13: geneeqn2004bs:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	215	100.0	215	3	AAA94740	Aaa94740 Human HSP
2	215	100.0	215	3	AAA94756	Aaa94756 Human HSP
3	215	100.0	2691	6	ABA99140	Ab99140 Human hsp
4	215	100.0	2691	6	ABK83917	Abk83917 Human cDN
5	215	100.0	2691	10	ADD14739	Add14739 Human src
6	214	99.5	2732	10	ADD29869	Add29869 Human tum
7	214	99.5	2767	12	ADQ87261	Adq87261 Human tum
8	214	99.5	2767	12	ADQ84979	Adq84979 Human tum
9	214	99.5	2767	13	ADQ83802	Adq83802 Human tum
10	214	99.5	5387	13	ADS89095	Ads89095 Human HSP
11	213.4	99.3	549	9	ADA45212	Ada45212 Human hsp
12	213.4	99.3	2465	2	AAT58086	Aat58086 Human hsp
13	213	99.1	213	12	ADO01084	Ado01084 Human hsp
14	212.4	98.8	2700	3	AAA97541	Aaa97541 Human hsp
15	210.4	97.9	1903	11	ADM02338	Adm02338 Human cDN
16	208.6	97.0	2465	3	AAA15620	Aaa15620 Human hsp
17	195	90.7	2387	12	ADL82938	Adl82938 Human hsp
18	195	90.7	2387	13	ADR25283	Adr25283 Breast ca
19	195	90.7	2387	13	ACN38447	Acn38447 Tumour-as
20	191.4	89.0	2412	12	ADE76979	Ad76979 Human cDN

C	22	186.2	86.6	2302	3	AAA15622	Aaa15622 Human hsp
C	22	186.2	86.6	511	4	AAH88560	Aah88560 CNS disor
C	23	185.2	86.1	2302	3	AAA15621	Aaa15621 Human hsp
C	24	163.6	76.1	506	12	ACH73362	Ach73362 Human gen
C	25	163.6	76.1	2876	8	ACA89884	Ac89884 Gene diff
C	26	156.8	72.9	2458	12	ADE76980	Ad76980 Human cDN
C	27	156.8	72.9	2513	10	ADD29868	Add29868 Human tum
C	28	145.2	67.5	595	6	ABQ30839	Abq30839 Oligonuc
C	29	145.2	67.5	595	6	ABQ30838	Abq30838 Oligonuc
C	30	145.2	67.5	596	6	ABQ34141	Abq34141 Oligonuc
C	31	145.2	67.5	596	6	ABQ34140	Abq34140 Oligonuc
C	32	145.2	67.5	5387	13	ADS89452	Ads89452 Oligonuc
C	33	145.2	67.5	9899	6	ABL34442	Ab134442 Human imm
C	34	134	62.3	595	6	ABQ30841	Abq30841 Oligonuc
C	35	134	62.3	595	6	ABQ30840	Abq30840 Oligonuc
C	36	134	62.3	596	6	ABQ34139	Abq34139 Oligonuc
C	37	134	62.3	596	6	ABQ34138	Abq34138 Oligonuc
C	38	134	62.3	5387	13	ADS89451	Ads89451 Oligonuc
C	39	134	62.3	9899	6	ABL34443	Ab134443 Human imm
C	40	116.6	54.2	2460	10	ADP76348	Adp76348 Novel hum
C	41	116.6	54.2	2460	12	ADO87260	Ado87260 Human tum
C	42	116.6	54.2	2460	12	ADO83801	Ado83801 Human tum
C	43	116.6	54.2	2460	13	ADQ84978	Adq84978 Human tum
C	44	116.6	54.2	2460	13	ACN38446	Acn38446 Tumour-as
C	45	113.8	52.9	5387	13	ADS89726	Ads89726 Oligonuc

## ALIGNMENTS

RESULT 1  
AAA94740  
ID AAA94740 standard; DNA; 215 BP.  
XX  
AC AAA94740;  
XX  
DT 19-JAN-2001 (first entry)  
XX  
DE Human HSP70A 5' untranslated region DNA sequence.  
XX  
KW Human; HSP70A; 5' UTR; untranslated region; heat shock protein;  
KW translation efficiency; vaccine; bacterial; viral; parasitic infection;  
KW immune-related disease; contraceptive; gene therapy; cancer;  
KW cardiovascular disorder; cystic fibrosis; de.  
XX  
OS Homo sapiens.  
XX  
PN WO200053785-A2.  
XX  
PD 14-SEP-2000.  
XX  
PF 09-MAR-2000; 2000WO-EP002031.  
XX  
PR 11-MAR-1999; 99GB-00005498.  
XX  
PA (GLAXO) GLAXO GROUP LTD.  
XX  
PI Coste HJ, Ellis JH;  
XX  
DR WPI; 2000-594331/56.  
XX  
PT Human heat shock protein 5' untranslated region (UTR) transcribed to  
PT provide an RNA molecule having UTR that increases translation efficiency  
PT of polypeptides, useful for treating deficiency in expression of the  
PT polypeptide.  
XX  
PS Claim 7, Page 28; 44pp; English.  
XX  
CC The present sequence is the 5' untranslated region (UTR) of human heat  
CC shock protein (Hsp) 70A gene. This sequence has a high potential to form  
CC secondary structures. This sequence can be used to increase the  
CC translation efficiency of a polypeptide. The present sequence may be  
CC useful in therapeutic or prophylactic vaccination for preventing



CC antigen or cell. The method can be used in the immunotherapy of cancer  
CC and pathogen infections, and for enhancing or reducing protein in a cell  
CC resistance of cells. The expression of the heat shock protein in a cell  
CC enhances the presentation of endogenous antigens by MHC class I molecules  
CC onto the cell surface in vitro, and can enhance the immunogenicity of the  
CC endogenous antigen in vivo, by enhancing the generation of antibodies to  
CC the otherwise poorly immunogenic antigen or cell. This sequence represents  
CC the cDNA of human hsp72

CC Sequence 2691 BP; 600 A; 780 C; 831 G; 480 T; 0 U; 0 Other;

Query Match 100.0%; Score 215; DB 6; Length 2691;  
Best Local Similarity 100.0%; Pred. No. 1.1e-54;  
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATAAAGCGCTAGCGCTGAGAGCTGCGGACAGTCCACTCTTTTCGAGAGTACTCCC 60  
DB 274 ATAAAGCGCTAGCGCTGAGAGCTGCGGACAGTCCACTCTTTTCGAGAGTACTCCC 333  
QY 61 GTTGTCCAAAGGCTTCCAGAGGAACTGTGCGGCTGAGGACCGCGCGCTGAGATT 120  
DB 334 GTTGTCCAAAGGCTTCCAGAGGAACTGTGCGGCTGAGGACCGCGCGCTGAGATT 393  
QY 121 CCGGCGTCCGGAAGACCGAGCTCTTCTGCGGATCAGTGTTCGTTCCAGCCCCCA 180  
DB 394 CCGGCGTCCGGAAGACCGAGCTCTTCTGCGGATCAGTGTTCGTTCCAGCCCCCA 453  
QY 181 TCTCAGAGCCGACCGACAGAGAGGAGAACCGC 215  
DB 454 TCTCAGAGCCGACCGACAGAGAGGAGAACCGC 488

RESULT 4

ABK83917 standard; cDNA; 2691 BP.

ID ABK83917

AC ABK83917;

DT 14-AUG-2002 (first entry)

DE Human cDNA differentially expressed in granulocytic cells #488.  
XX  
XX Human; ss; granulocytic cell; DNA chip; bacterial infection;  
KW viral infection; parasitic infection; protozoal infection;  
KW fungal infection; sterile inflammatory disease; psoriasis;  
KW rheumatoid arthritis; glomerulonephritis; asthma; thrombosis;  
KW cardiac reperfusion injury; renal reperfusion injury; ARDS;  
KW adult respiratory distress syndrome; inflammatory bowel disease;  
KW Crohn's disease; ulcerative colitis; periodontal disease;  
KW granulocyte activation; chronic inflammation; allergy.

OS Homo sapiens.

PN WO200228999-A2.

PD 11-APR-2002.

XX 03-OCT-2001; 2001WO-US030821.

PR 03-OCT-2000; 2000US-0237189P.

XX (GENE-) GENE LOGIC INC.

PA Beazer-Barclay Y, Weisman SM, Yamaga S, Vockley J;

PI WPI; 2002-435328/46.

DR Detecting granulocyte activation by detecting differential expression of  
XX genes associated with granulocyte activation, which serves as diagnostic  
XX markers that is useful for monitoring disease states and drug toxicity.  
XX Claim 1; SEQ ID NO 488; 114bp; English.

CC The invention relates to detecting (M1) granulocyte (GC) activation  
CC (GCA), by detecting the level of expression of gene(s) identified by  
CC DNA chip analysis as given in the specification, and comparing the  
CC expression level to an expression level in an unactivated GC, where  
CC differential expression of Gs is indicative of GCA. Also included are  
CC modulating (M2) Gs by contacting GC with an agent that alters the  
CC expression of at least one gene in Gs; (2) screening (M3) for an agent  
CC capable of modulating GCA or an inflammation (especially chronic) in a  
CC tissue, an allergic response in a subject, exposure of a subject to a  
CC pathogen or sterile inflammatory disease using the gene expression  
CC profile; (3) detecting (M4) an inflammation (especially chronic) in a  
CC tissue, an allergic response in a subject, exposure of a subject to a  
CC pathogen or sterile inflammatory disease, by detecting the level of  
CC expression in a sample of the tissue of gene(s) from Gs, where the level  
CC of expression of the gene is indicative of inflammation; (4) treating  
CC (M5) an inflammation (especially chronic) or in a tissue, an allergic  
CC response in a subject, exposure of a subject to a pathogen or sterile  
CC inflammatory disease, by contacting a tissue having inflammation with an  
CC agent that modulates the expression of gene(s) from Gs in the tissue. M1  
CC is useful for detecting GCA; M2 is useful for modulating GCA; M3 is useful  
CC for screening an agent capable of modulating GCA preferably in an  
CC inflammation in a tissue; M4 is useful for detecting an inflammation  
CC (especially chronic) in a tissue, an allergic response in a subject,  
CC exposure of a subject to a pathogen or sterile inflammatory disease (e.g.  
CC psoriasis, rheumatoid arthritis, glomerulonephritis, asthma, thrombosis,  
CC cardiac reperfusion injury, renal reperfusion injury, ARDS, adult  
CC respiratory distress syndrome, inflammatory bowel disease, Crohn's  
CC disease, ulcerative colitis, periodontal disease; also bacterial  
CC infection, viral infection, parasitic infection, protozoal infection,  
CC fungal infection and M5 is useful for treating one of the above  
CC conditions. The present sequence represents a gene differentially  
CC expressed in granulocytes. Note: The sequence data for this patent did  
CC not form part of the printed specification, but was obtained in  
CC electronic format directly from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences

CC Sequence 2691 BP; 600 A; 780 C; 831 G; 480 T; 0 U; 0 Other;

Query Match 100.0%; Score 215; DB 6; Length 2691;  
Best Local Similarity 100.0%; Pred. No. 1.1e-54;  
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATAAAGCGCTAGCGCTGAGAGCTGCGGACAGTCCACTCTTTTCGAGAGTACTCCC 60  
DB 274 ATAAAGCGCTAGCGCTGAGAGCTGCGGACAGTCCACTCTTTTCGAGAGTACTCCC 333  
QY 61 GTTGTCCAAAGGCTTCCAGAGGAACTGTGCGGCTGAGGACCGCGCGCTGAGATT 120  
DB 334 GTTGTCCAAAGGCTTCCAGAGGAACTGTGCGGCTGAGGACCGCGCGCTGAGATT 393  
QY 121 CCGGCGTCCGGAAGACCGAGCTCTTCTGCGGATCAGTGTTCGTTCCAGCCCCCA 180  
DB 394 CCGGCGTCCGGAAGACCGAGCTCTTCTGCGGATCAGTGTTCGTTCCAGCCCCCA 453  
QY 181 TCTCAGAGCCGACCGACAGAGAGGAGAACCGC 215  
DB 454 TCTCAGAGCCGACCGACAGAGAGGAGAACCGC 488

RESULT 5

ADD14739 standard; cDNA; 2691 BP.

ID ADD14739

AC ADD14739;

DT 01-JAN-2004 (first entry)

DE Human src biomarker polynucleotide SEQ ID NO:133.  
XX  
XX predictor set; protein tyrosine kinase activity modulator;  
KW protein tyrosine kinase pathway; protein tyrosine kinase; cytosolic;  
KW gene therapy; drug sensitivity; genetic profile; cancer; human; gene; ss.

OS Homo sapiens.  
XX WO2003062395-A2.  
XX 31-JUL-2003.  
XX  
XX 17-JAN-2003; 2003WO-US001981.  
XX  
XX 18-JAN-2002; 2002US-0350061P.  
XX  
XX (BRIM ) BRISTOL-MYERS SQUIBB CO.  
XX  
XX Huang F, Faichild CR, Lee FY, Shaw P,  
XX WPI; 2003-636735/60.  
XX P-PSDB; ADD14137.  
XX  
XX New polynucleotides and polypeptides for predicting the activity of  
PT compounds that interact with protein tyrosine kinases and/or protein  
PT tyrosine kinase pathways.  
XX  
XX Claim 2; SEQ ID NO 133; 139pp; English.  
XX  
XX The present invention describes a predictor set comprising a plurality of  
CC polynucleotides or polypeptides whose expression pattern is predictive of  
CC the response of cells to treatment with a compound that modulates protein  
CC tyrosine kinase activity or members of the protein tyrosine kinase  
CC pathway. Also described: (1) predicting whether a compound is capable of  
CC modulating the activity of cells, comprising obtaining a sample of cells,  
CC determining whether the cells express a plurality of markers, and  
CC correlating the expression of the markers to the compound's ability to  
CC modulate the activity of the cells; (2) a plurality of cell lines for  
CC identifying polynucleotides and polypeptides whose expression levels  
CC correlate with compound sensitivity or resistance of cells associated  
CC with a disease state; and (3) identifying polynucleotides and  
CC polypeptides that predict compound sensitivity or resistance of cells  
CC associated with a disease state, comprising subjecting the plurality of  
CC cell lines to one or more compounds, analysing the expression pattern of  
CC a microarray of polynucleotides or polypeptides, and selecting  
CC polynucleotides or polypeptides that predict the sensitivity or  
CC resistance of cells associated with a disease state by using the  
CC expression pattern of the microarray. The polynucleotides and  
CC polypeptides have cytoskeletal activities, and can be used in gene therapy.  
CC The polynucleotides and polypeptides are useful in predicting the  
CC activity of compounds that interact with protein tyrosine kinases and/or  
CC protein tyrosine kinase pathways. These may be used in determining drug  
CC sensitivity in patients to allow the development of individualized  
CC genetic profiles which aid in treating diseases and disorders (e.g.  
CC cancer) based on patient response at a molecular level. The present  
CC sequence is used in the exemplification of the present invention.  
XX  
SQ Sequence 2691 BP; 600 A; 780 C; 831 G; 480 T; 0 U; 0 Other;  
Query Match 100.0%; Score 215; DB 10; Length 2691;  
Best Local Similarity 100.0%; Pred. No. 1.1e-54;  
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 ATAAAGGCTAGGCTGAGAGCTGTCGACAGTCACTCACTTTTTCGAGAGTACTCCC 60  
DB 274 ATAAAGGCTAGGCTGAGAGCTGTCGACAGTCACTCACTTTTTCGAGAGTACTCCC 333  
QY 61 GTTGTCCCAAGGCTTCCAGAGGAACTGTGGGCTGAGGACCGGGCGCTGAGTTT 120  
DB 334 GTTGTCCCAAGGCTTCCAGAGGAACTGTGGGCTGAGGACCGGGCGCTGAGTTT 393  
QY 121 CCGGCGCTCGGAAGAGCCGAGCTTCTTCGCGGATCACTAGTTCGTTTCCAGCCCCCA 180  
DB 394 CCGGCGCTCGGAAGAGCCGAGCTTCTTCGCGGATCACTAGTTCGTTTCCAGCCCCCA 453  
QY 181 TCTCAGAGCCGAGCCGACAGAGAGAGGAAACCGC 215  
DB 454 TCTCAGAGCCGAGCCGACAGAGAGAGGAAACCGC 488

RESULT 6  
ADD29869  
ID ADD29869 strand; mRNA; 2732 BP.  
XX  
XX ADD29869;  
XX  
XX 15-JAN-2004 (first entry)  
XX  
XX Human tumour suppressor mRNA SEQ ID NO:300.  
XX  
XX ss; human; tumour suppressor; cancer; cancer; cytostatic; gene therapy.  
XX  
XX Homo sapiens.  
XX  
XX WO2003058201-A2.  
XX  
XX 17-JUL-2003.  
XX  
XX 31-DEC-2002; 2002WO-US041825.  
XX  
XX 31-DEC-2001; 2001US-0345317P.  
XX  
XX (QUAR-) QUARK BIOTECH INC.  
XX (CLEV-) CLEVELAND CLINIC FOUND.  
XX  
XX Feinstein B, Gudkov AV;  
XX  
XX WPI; 2003-598393/56.  
XX  
XX Diagnosing cancer comprises determining the polypeptide or polynucleotide  
PT levels e.g., hepatic lipase, in a sample from a subject, where a higher  
PT level compared to that in a subject free of cancer is indicative of  
PT cancer.  
XX  
XX Disclosure; SEQ ID NO 300; 272pp; English.  
XX  
XX The invention relates to a novel method for diagnosing a cancer in a  
CC subject, the method comprises determining, in a sample from the subject,  
CC the level of at least one polypeptide, where a higher level of the  
CC polypeptide compared to the level of the polypeptide in a subject free of  
CC cancer is indicative of cancer. The polypeptide is selected from any of  
CC the polypeptides encoded by the polynucleotides listed in the  
CC specification and polypeptides which are at least 70% homologous to the  
CC polypeptides. The method of the invention has cytoskeletal activity, and  
CC may have a use in gene therapy. The method is useful in identifying  
CC markers specific for one or several types of cancer, depending on the  
CC tissue origin, which may be used in numerous diagnostic and prognostic  
CC applications as well as cancer type-specific targets for therapeutic  
CC intervention. The compounds that modulate the activity of a tumour  
CC suppressor gene are useful in the treatment of cancer or as anti-cancer  
CC drugs. The present sequence represents a polynucleotide of the invention.  
XX  
SQ Sequence 2732 BP; 608 A; 787 C; 840 G; 497 T; 0 U; 0 Other;  
Query Match 99.5%; Score 214; DB 10; Length 2732;  
Best Local Similarity 100.0%; Pred. No. 2.3e-54;  
Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 ATAAAGGCTAGGCTGAGAGCTGTCGACAGTCACTCACTTTTTCGAGAGTACTCCC 60  
DB 274 ATAAAGGCTAGGCTGAGAGCTGTCGACAGTCACTCACTTTTTCGAGAGTACTCCC 333  
QY 61 GTTGTCCCAAGGCTTCCAGAGGAACTGTGGGCTGAGGACCGGGCGCTGAGTTT 120  
DB 334 GTTGTCCCAAGGCTTCCAGAGGAACTGTGGGCTGAGGACCGGGCGCTGAGTTT 393  
QY 121 CCGGCGCTCGGAAGAGCCGAGCTTCTTCGCGGATCACTAGTTCGTTTCCAGCCCCCA 180  
DB 394 CCGGCGCTCGGAAGAGCCGAGCTTCTTCGCGGATCACTAGTTCGTTTCCAGCCCCCA 453  
QY 181 TCTCAGAGCCGAGCCGACAGAGAGAGGAAACCG 214

DB 454 TCTCAGAGCCGAGCCGAGAGAGGAGGAAACCG 487

RESULT 7

ID ADQ87261 standard; cDNA; 2767 BP.

AC ADQ87261;

XX 07-OCT-2004 (first entry)

DT

XX Human tumour-associated antigenic target (TAT) cDNA sequence #4138.

DE human; tumour-associated antigenic target; TAT; cytostatic; gene therapy;

XX cancer; cell proliferative disorder; gene; ss.

OS Homo sapiens.

XX WO2004060270-A2.

PN

XX 22-JUL-2004.

PD

XX 15-OCT-2003; 2003WO-US029126.

PF

XX 18-OCT-2002; 2002US-0418988P.

PR

XX (GENENTECH INC.

PA (WUTD/) WU T D.

PA (ZHOU/) ZHOU Y.

PI Wu TD, Zhou Y;

XX Wu TD, Zhou Y;

PI MPI; 2004-534300/51.

DR

XX New nucleic acid molecule and encoded polypeptide, for diagnosing,

PT preventing or treating cell proliferative disorders such as cancer.

XX

PS Claim 1, SEQ ID NO 4138; 5504bp; English.

XX

CC The present invention describes an isolated tumour-associated antigenic

CC target (TAT) nucleic acid comprising: (a) any of 4622 nucleotide

CC sequences (see SEQ ID NO:1 to 4622); (b) the full-length coding region of

CC (a); (c) the complement of (a) or (b); (d) a sequence that has 80%

CC sequence identity to (a)-(c); or (e) a sequence that hybridises to (a)-

CC (c). Also described: (1) an expression vector comprising the above

CC nucleic acid; (2) a host cell comprising the above expression vector; (3)

CC a process for producing a polypeptide; (4) an isolated polypeptide

CC comprising: (a) an amino acid sequence encoded by any of the above

CC nucleotide sequences; (b) an amino acid sequence encoded by the full-

CC length coding region of the above nucleotide sequences; or (c) a sequence

CC having at least 80% identical to (a) or (b); (5) a chimeric polypeptide

CC comprising the above polypeptide fused to a heterologous polypeptide; (6)

CC an isolated antibody that binds to the above polypeptide; (7) a process

CC for producing the antibody; (8) an isolated oligopeptide that binds to

CC the above polypeptide; (9) a tumour-associated antigenic target (TAT)

CC binding organic molecule that binds to the above polypeptide; (10) a

CC composition of matter comprising the above (chimeric) polypeptide,

CC antibody, oligopeptide or TAT binding organic molecule, in combination

CC with a carrier; (11) an article of manufacture comprising a container and

CC the composition of matter contained within the container; (12) methods of

CC inhibiting the growth of a cell that expresses the above protein, where

CC the growth of the cell is at least in part dependent upon a growth

CC potentiating effect of the above protein; (13) a method of

CC therapeutically treating a mammal having a cancerous tumour comprising

CC cells that express the above protein; (14) a method of determining the

CC presence of a protein in a sample suspected of containing the protein

CC described above; (15) methods of diagnosing the presence of a tumour in a

CC mammal; (16) a method for treating or preventing a cell proliferative

CC disorder associated with increased expression or activity of the above

CC protein; and (17) a method of binding an antibody, oligopeptide or

CC organic molecule to a cell that expresses the protein described above.

CC The TAT sequences have cytostatic activities, and can be used in gene

CC therapy. The composition and methods are useful for diagnosing,

CC preventing or treating cancer. The composition is also used for preparing

CC a medicament for the therapeutic treatment or diagnostic detection of a

CC cell proliferative disorder or cancer. The present sequence represents a

CC human TAT cDNA sequence from the present invention.

XX

XX Sequence 2767 BP; 621 A; 808 C; 854 G; 484 T; 0 U; 0 Other;

SQ

Query Match 99.5%; Score 214; DB 12; Length 2767;

Best Local Similarity 100.0%; Pred. No. 2.3e-54;

Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX

QY 1 ATPACGGCTTACCTTGAAGAGCTGTCGACAGTCCACTTCTTTTTCAGAGTACTCCC 60

DB 362 ATPACGGCTTACCTTGAAGAGCTGTCGACAGTCCACTTCTTTTTCAGAGTACTCCC 421

QY 61 GTTGTCCCAAGGCTTCCAGAGCGAACCCTGTGCGCTGACGACACCGGCGTCCAGATT 120

DB 422 GTTGTCCCAAGGCTTCCAGAGCGAACCCTGTGCGCTGACGACACCGGCGTCCAGATT 481

QY 121 CCGGCGTCCGGAAGACCGAGCTTCTCGCGAATCCAGTTCGTTCCAGCCCCCAA 180

DB 482 CCGGCGTCCGGAAGACCGAGCTTCTCGCGAATCCAGTTCGTTCCAGCCCCCAA 541

QY 181 TCTCAGAGCCGAGCCGAGAGAGGAGGAAACCG 214

DB 542 TCTCAGAGCCGAGCCGAGAGAGGAGGAAACCG 575

RESULT 8

ADQ84979

ID ADQ84979 standard; cDNA; 2767 BP.

XX

AC ADQ84979;

XX

DT 07-OCT-2004 (first entry)

XX

DE Human tumour-associated antigenic target (TAT) cDNA sequence #1793.

XX

XX human; tumour-associated antigenic target; TAT; cytostatic; gene therapy;

KW cancer; cell proliferative disorder; gene; ss.

XX

OS Homo sapiens.

XX

PN WO2004060270-A2.

XX

PD 22-JUL-2004.

XX

XX 15-OCT-2003; 2003WO-US029126.

PF

XX 18-OCT-2002; 2002US-0418988P.

PR

XX (GENENTECH INC.

PA (WUTD/) WU T D.

PA (ZHOU/) ZHOU Y.

PI Wu TD, Zhou Y;

XX Wu TD, Zhou Y;

PI MPI; 2004-534300/51.

DR

XX New nucleic acid molecule and encoded polypeptide, for diagnosing,

PT preventing or treating cell proliferative disorders such as cancer.

XX

PS Claim 1, SEQ ID NO 1793; 5504bp; English.

XX

CC The present invention describes an isolated tumour-associated antigenic

CC target (TAT) nucleic acid comprising: (a) any of 4622 nucleotide

CC sequences (see SEQ ID NO:1 to 4622); (b) the full-length coding region of

CC (a); (c) the complement of (a) or (b); (d) a sequence that has 80%

CC sequence identity to (a)-(c); or (e) a sequence that hybridises to (a)-

CC (c). Also described: (1) an expression vector comprising the above

CC nucleic acid; (2) a host cell comprising the above expression vector; (3)

CC a process for producing a polypeptide; (4) an isolated polypeptide

CC comprising: (a) an amino acid sequence encoded by any of the above

CC nucleotide sequences; (b) an amino acid sequence encoded by the full-  
 CC length coding region of the above nucleotide sequences; or (c) a sequence  
 CC having at least 80% identical to (a) or (b); (5) a chimeric polypeptide  
 CC comprising the above polypeptide fused to a heterologous polypeptide; (6)  
 CC an isolated antibody that binds to the above polypeptide; (7) a process  
 CC for producing the antibody; (8) an isolated oligopeptide that binds to  
 CC the above polypeptide; (9) a tumour-associated antigenic target (TAT)  
 CC binding organic molecule that binds to the above polypeptide; (10) a  
 CC composition of matter comprising the above (chimeric) polypeptide,  
 CC antibody, oligopeptide or TAT binding organic molecule, in combination  
 CC with a carrier; (11) an article of manufacture comprising a container and  
 CC the composition of matter contained within the container; (12) methods of  
 CC inhibiting the growth of a cell that expresses the above protein, where  
 CC the growth of the cell is at least in part dependent upon a growth  
 CC potentiating effect of the above protein; (13) a method of  
 CC therapeutically treating a mammal having a cancerous tumour comprising  
 CC cells that express the above protein; (14) a method of determining the  
 CC presence of a protein in a sample suspected of containing the protein in a  
 CC described above; (15) methods of diagnosing the presence of a tumour in a  
 CC mammal; (16) a method for treating or preventing a cell proliferative  
 CC disorder associated with increased expression or activity of the above  
 CC protein; and (17) a method of binding an antibody, oligopeptide or  
 CC organic molecule to a cell that expresses the protein described above.  
 CC The TAT sequences have cytostatic activities, and can be used in gene  
 CC therapy. The composition and methods are useful for diagnosing,  
 CC preventing or treating cancer. The composition is also used for preparing  
 CC a medicament for the therapeutic treatment or diagnostic detection of a  
 CC cell proliferative disorder or cancer. The present sequence represents a  
 CC human TAT cDNA sequence from the present invention.

XX Sequence 2767 BP; 621 A; 809 C; 853 G; 484 T; 0 U; 0 Other;

Query Match 99.5%; Score 214; DB 12; Length 2767;  
 Best Local Similarity 100.0%; Pred. No. 2.3e-54;  
 Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 ATAAACGGCTAGCTGAGAGCTGCTGCAAGCTCACTTCTTTCAGAGTGAATCCC 60  
 Db 362 ATAAACGGCTAGCTGAGAGCTGCTGCAAGCTCACTTCTTTCAGAGTGAATCCC 421  
 QY 61 GTTGTCCCAAGGCTTCCAGAGCGAAGCTGTGGGCTGAGGACCGGCGCTCGAGTTT 120  
 Db 422 GTTGTCCCAAGGCTTCCAGAGCGAAGCTGTGGGCTGAGGACCGGCGCTCGAGTTT 481  
 QY 121 CCGGCGCTCGAAGAGACCGAGCTCTTCTCGCGGATCCAGTGTTCGTTTCCAGCCCCCA 180  
 Db 482 CCGGCGCTCGAAGAGACCGAGCTCTTCTCGCGGATCCAGTGTTCGTTTCCAGCCCCCA 541  
 QY 181 TCTCAGAGCCGAGCCGACAGAGAGGAGGAAACCG 214  
 Db 542 TCTCAGAGCCGAGCCGACAGAGAGGAGGAAACCG 575

RESULT 9

AD083802  
 ID AD083802 standard; cDNA, 2767 BP.

AC AD083802;  
 XX  
 DT 07-OCT-2004 (first entry)  
 XX  
 DE Human tumour-associated antigenic target (TAT) cDNA sequence #616.  
 XX  
 KW human; tumour-associated antigenic target; TAT; cytostatic; gene therapy;  
 KM cancer; cell proliferative disorder; gene; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2004060270-A2.  
 XX  
 PD 22-JUL-2004.  
 XX  
 PF 15-OCT-2003; 2003WO-US029126.

XX 18-OCT-2002; 2002US-0418988P.  
 PR  
 XX (GENTH) GENENTECH INC.  
 PA (WU/TD) WU T D.  
 PA (ZHOU/) ZHOU Y.  
 XX  
 PI Wu TD, Zhou Y;  
 DR WPI; 2004-534300/51.  
 PT New nucleic acid molecule and encoded polypeptide, for diagnosing,  
 PT preventing or treating cell proliferative disorders such as cancer.  
 XX  
 PS Claim 1; SEQ ID NO 616; 5504pp; English.

The present invention describes an isolated tumour-associated antigenic  
 CC target (TAT) nucleic acid comprising: (a) any of 4622 nucleotide  
 CC sequences (see SEQ ID NO:1 to 4622); (b) the full-length coding region of  
 CC (a); (c) the complement of (a) or (b); (d) a sequence that has 80%  
 CC sequence identity to (a)-(c); or (e) a sequence that hybridizes to (a)-  
 CC (c). Also described: (1) an expression vector comprising the above  
 CC nucleic acid; (2) a host cell comprising the above expression vector; (3)  
 CC a process for producing a polypeptide; (4) an isolated polypeptide  
 CC comprising: (a) an amino acid sequence encoded by any of the above  
 CC nucleotide sequences; (b) an amino acid sequence encoded by the full-  
 CC length coding region of the above nucleotide sequences; or (c) a sequence  
 CC having at least 80% identical to (a) or (b); (5) a chimeric polypeptide  
 CC comprising the above polypeptide fused to a heterologous polypeptide; (6)  
 CC an isolated antibody that binds to the above polypeptide; (7) a process  
 CC for producing the antibody; (8) an isolated oligopeptide that binds to  
 CC the above polypeptide; (9) a tumour-associated antigenic target (TAT)  
 CC binding organic molecule that binds to the above polypeptide; (10) a  
 CC composition of matter comprising the above (chimeric) polypeptide,  
 CC antibody, oligopeptide or TAT binding organic molecule, in combination  
 CC with a carrier; (11) an article of manufacture comprising a container and  
 CC the composition of matter contained within the container; (12) methods of  
 CC inhibiting the growth of a cell that expresses the above protein, where  
 CC the growth of the cell is at least in part dependent upon a growth  
 CC potentiating effect of the above protein; (13) a method of  
 CC therapeutically treating a mammal having a cancerous tumour comprising  
 CC cells that express the above protein; (14) a method of determining the  
 CC presence of a protein in a sample suspected of containing the protein in a  
 CC described above; (15) methods of diagnosing the presence of a tumour in a  
 CC mammal; (16) a method for treating or preventing a cell proliferative  
 CC disorder associated with increased expression or activity of the above  
 CC protein; and (17) a method of binding an antibody, oligopeptide or  
 CC organic molecule to a cell that expresses the protein described above.  
 CC The TAT sequences have cytostatic activities, and can be used in gene  
 CC therapy. The composition and methods are useful for diagnosing,  
 CC preventing or treating cancer. The composition is also used for preparing  
 CC a medicament for the therapeutic treatment or diagnostic detection of a  
 CC cell proliferative disorder or cancer. The present sequence represents a  
 CC human TAT cDNA sequence from the present invention.

XX Sequence 2767 BP; 621 A; 808 C; 854 G; 484 T; 0 U; 0 Other;

Query Match 99.5%; Score 214; DB 13; Length 2767;  
 Best Local Similarity 100.0%; Pred. No. 2.3e-54;  
 Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATAAACGGCTAGCTGAGAGCTGCTGCAAGCTCACTTCTTTCAGAGTGAATCCC 60  
 Db 362 ATAAACGGCTAGCTGAGAGCTGCTGCAAGCTCACTTCTTTCAGAGTGAATCCC 421  
 QY 61 GTTGTCCCAAGGCTTCCAGAGCGAAGCTGTGGGCTGAGGACCGGCGCTCGAGTTT 120  
 Db 422 GTTGTCCCAAGGCTTCCAGAGCGAAGCTGTGGGCTGAGGACCGGCGCTCGAGTTT 481  
 QY 121 CCGGCGCTCGAAGAGACCGAGCTCTTCTCGCGGATCCAGTGTTCGTTTCCAGCCCCCA 180  
 Db 482 CCGGCGCTCGAAGAGACCGAGCTCTTCTCGCGGATCCAGTGTTCGTTTCCAGCCCCCA 541



```
Db 329 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGCAGGACCGGCGCTCGAGTTT 388
Qy 121 CCGGCGTCGGAAGACCGAGCTTCTTCGCGGATCCAGTGTTCGTTTCCAGCCCCCA 180
Db 369 CCGGCGTCGGAAGACCGAGCTTCTTCGCGGATCCAGTGTTCGTTTCCAGCCCCCA 448
Qy 181 TCTCAGAGCCGAGCCGACAGAGAGCGGAAACCGC 215
Db 449 TCTCAGAGCCGAGCCGACAGAGAGCGGAAACCGC 483

RESULT 12
AAT58086
ID AAT58086 standard; cDNA, 2465 BP.
XX
XX AAT58086;
XX
XX 24-OCT-1997 (first entry)
XX
XX Human heat shock protein 70 cDNA.
XX
XX Human heat shock protein 70; HSP70; primer; probe; detection;
XX intracellular; abnormal transcription; acute; chronic; sustained; stress;
XX es.
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX CDS 263..2185
XX FT /*tag= "a"
XX FT /product= "HSP70"
XX
XX JP08322577-A.
XX
XX 10-DEC-1996.
XX
XX 01-JUN-1995; 95JP-00158581.
XX
XX 01-JUN-1995; 95JP-00158581.
XX
XX (HOKE-) HOKEN KAGAKU KENKYUSHO KK.
XX WPI; 1997-081088/08.
XX P-PSDB; AAW10065.
XX
XX Detection of abnormal transcription of HSP70 mRNA - using HSP70 specific
XX primer or probe, used in detection of human acute and chronic sustained
XX stress load.
XX
XX Claim 1; Fig 1; 13pp; Japanese.
XX
XX The present sequence, which encodes human heat shock protein 70 (HSP70),
XX is located on human chromosome 6p 21.3-22 and 14q 22-24 and 21. Primers
XX and probes based on the HSP70 cDNA coding sequence can be used to detect
XX the abnormal transcription of intracellular HSP70 mRNA in human acute and
XX chronic sustained stress load
XX
XX Sequence 2465 BP; 553 A; 713 C; 758 G; 441 T; 0 U; 0 Other;
XX
XX Query Match 99.3%; Score 213.4; DB 2; Length 2465;
XX Best Local Similarity 99.5%; Pred. No. 3,4e-54;
XX Matches 214; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 AATAAGCGCTAGCGTCTGAGAGCTGCTGCGACAGTCACTACCTTTTCGAGAGTACTCC 60
Db 48 AATAAGCGCTAGCGTCTGAGAGCTGCTGCGACAGTCACTACCTTTTCGAGAGTACTCC 107
Qy 61 GTTGTCCCAAGGCTTCCAGAGGAACTGTGCGGCTGCAGGACCGGCGCTCGAGTTT 120
Db 108 GTTGTCCCAAGGCTTCCAGAGGAACTGTGCGGCTGCAGGACCGGCGCTCGAGTTT 167
Qy 121 CCGGCGTCGGAAGACCGAGCTTCTTCGCGGATCCAGTGTTCGTTTCCAGCCCCCA 180
```

```
Db 168 CCGGCGTCGGAAGACCGAGCTTCTTCGCGGATCCAGTGTTCGTTTCCAGCCCCCA 227
Qy 181 TCTCAGAGCCGAGCCGACAGAGAGCGGAAACCGC 215
Db 228 TCTCAGAGCCGAGCCGACAGAGAGCGGAAACCGC 262

RESULT 13
AD001084
ID AD001084 standard; DNA, 213 BP.
XX
XX AD001084;
XX
XX 29-JUL-2004 (first entry)
XX
XX Human hsp70 translational enhancer element DNA sequence SEQ ID NO:6.
XX
XX Increasing glycogen; toxic; toxic glycogen level; glycogen;
XX cell proliferative disorder; tumour therapy; anti-tumour therapy;
XX anti-cell proliferative; cytostatic; gene therapy; sarcoma; melanoma;
XX myeloma; blastoma; glioma; lymphoma; leukaemia; human;
XX heat shock protein 70; chromosome 6; hsp70; gene; ds.
XX
XX Homo sapiens.
XX
XX WO2004039412-A2.
XX
XX 13-MAY-2004.
XX
XX 29-OCT-2003; 2003WO-1B005562.
XX
XX 29-OCT-2002; 2002US-0422365P.
XX
XX (ENGGE-) ENGGENE INC.
XX
XX Doiron B, Pownall S, Cheung A, Hsu E;
XX WPI; 2004-376072/35.
XX GENBANK; M11717.
XX
XX Increasing glycogen to toxic levels in a cell, useful for treating cell
XX proliferative disorder, comprises expressing in a cell a gene product
XX that increases the amount of glycogen to toxic levels in the cell.
XX
XX Example 1; SEQ ID NO 6; 98pp; English.
XX
XX The present invention describes a method for increasing glycogen to toxic
XX levels in a cell. The method comprises expressing in a cell a gene
XX product that increases the amount of glycogen to toxic levels in the
XX cell. Also described: (1) treating a cell proliferative disorder in a
XX subject, where the cell proliferative disorder is not a liver, muscle or
XX brain cell disorder, by expressing in one or more cells comprising the
XX disorder a gene product that increases the amount of intracellular
XX glycogen, or contacting one or more cells comprising the disorder with an
XX agent that increases the amount of intracellular glycogen, sufficient to
XX treat the cell proliferative disorder; (2) treating a subject that is
XX undergoing or has undergone tumour therapy, where the tumour therapy was
XX not for liver, muscle or brain tumour by administering to the subject an
XX agent in an amount that increases the amount of intracellular glycogen in
XX a cell; (3) increasing effectiveness of an anti-tumour therapy; (4)
XX identifying an agent (A) having anti-cell proliferative activity; and (5)
XX to a kit comprising the agent, and instructions for administering the agent
XX to a subject in need of treatment on a label or packaging insert. (A) has
XX cytostatic activity, and can be used in gene therapy. The methods are
XX useful for treating a cell proliferative disorder, e.g. tumour, such as
XX sarcoma, melanoma, myeloma, blastoma, glioma, lymphoma or leukaemia. The
XX present sequence represents a translation enhancer element in the 5'
XX untranslated region of a human heat shock protein 70 (hsp70) sequence
XX comprising nucleotides 276 to 488 from the human hsp70 nucleotide
XX sequence of GenBank accession number M11717, which is used in an example
XX from the present invention. Human hsp70 is located on chromosome 6, more
XX specifically 6p21.3.
```



Sequence 213 BP; 40 A; 71 C; 63 G; 39 T; 0 U; 0 Other;  
Query Match 99.1%; Score 213; DB 12; Length 213;  
Best Local Similarity 100.0%; Pred. No. 2.6e-54;  
Matches 213; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 AACGGCTAGCTGAGAGAGTGTCTGCGACAGTCCACTACTTTTTCAGAGTGAATCCCGT 62  
DB 1 AACGGCTAGCTGAGAGAGTGTCTGCGACAGTCCACTACTTTTTCAGAGTGAATCCCGT 60  
QY 63 TGTCCCAAGGCTTCCAGAGCGCAACCTGTGCGGCTGACAGACCCGCGGTGAGTTCC 122  
DB 61 TGTCCCAAGGCTTCCAGAGCGCAACCTGTGCGGCTGACAGACCCGCGGTGAGTTCC 120  
QY 123 GCGGTCCGAGAGAGAGAGCTCTTCTCGCGGATCCAGTGTTCGTTCCAGCCCCCAATC 182  
DB 121 GCGGTCCGAGAGAGAGAGCTCTTCTCGCGGATCCAGTGTTCGTTCCAGCCCCCAATC 180  
QY 183 TCAGAGCCGAGCCGACAGAGAGAGGAAACCGC 215  
DB 181 TCAGAGCCGAGCCGACAGAGAGAGGAAACCGC 213

RESULT 14  
AAA97541  
ID AAA97541 standard; cDNA; 2700 BP.  
XX  
AC AAA97541;  
XX  
DT 29-JAN-2001 (first entry)  
XX  
DE Human Hep72 (heat shock protein 72) cDNA.  
XX  
KW Human Hep72; heat shock protein 72; chromosome 6p21.3; Hsp72 inhibitor;  
KW expression modulator; JNK phosphatase inhibitor; antiproliferative;  
KW drug screening; cancer; leukemia; lymphoma; solid tumor; sarcoma;  
KW carcinoma; breast cancer; prostate cancer; premalignant condition; ss.  
OS Homo sapiens.  
XX  
PN WO200054814-A1.  
XX  
PD 21-SEP-2000.  
XX  
PF 17-MAR-2000; 2000WO-US007350.  
XX  
PR 18-MAR-1999; 99US-0125046P.  
XX  
PA (PHYL-) PHYLOGENY INC.  
XX  
PI Volloch VZ, Sherman M;  
XX  
PI MPI; 2000-647056/62.  
XX  
DR P-PSDB; AAB23252.  
XX  
PT Identifying compounds that inhibit proliferation of cells and capable of  
PT modulating the expression of heat shock protein 72 gene and/or activity  
PT of Hsp72 useful for treating cancers such as leukemia, lymphoma.  
XX  
XX Example; Fig 16A; 77pp; English.  
XX  
XX The invention relates to a novel method of identifying compounds that  
XX inhibit proliferation of cells comprising contacting a test compound with  
XX a cell which overexpresses Hsp72 (heat shock protein 72), and determining  
XX if the test compound inhibits activity or expression of Hsp72.  
XX Optionally, Hsp72 is contacted with the test compound under optimum  
XX conditions to allow the two components to interact and bind, forming a  
XX complex which is detected. The invention also relates to a method of  
XX identifying compounds that inhibit Hsp72-mediated JNK phosphatase  
XX activation, comprising contacting a test compound with a cell which  
XX expresses Hsp72, exposing the cell to a heat induced stress and  
XX determining if the compound inhibits JNK phosphatase activity. The  
XX invention additionally encompasses compositions comprising an inhibitor

CC of Hsp72 or JNK phosphatase activity. The compounds identified as  
CC inhibitors of Hsp72 or JNK phosphatase activity are useful for inhibiting  
CC the proliferation of cells. Modulation of the activity of the JNK  
CC phosphatase or Hsp72 is used to treat a proliferative disorder such as  
CC cancers (e.g., leukemia, lymphoma, solid tumours such as sarcomas and  
CC carcinomas, breast cancer, prostate cancer). The compounds that inhibit  
CC Hsp72 activity can also be administered to treat premalignant conditions  
CC and to prevent progression to a neoplastic or malignant state. The  
CC compounds that inhibit Hsp72 function are administered to a patient  
CC having a disease or disorder mediated by an increase of Hsp72 expression  
CC or activity relative to normal levels. The present sequence represents  
CC cDNA encoding human Hsp72 used in the exemplifications of the invention  
XX

Sequence 2700 BP; 601 A; 780 C; 834 G; 485 T; 0 U; 0 Other;  
Query Match 98.8%; Score 212.4; DB 3; Length 2700;  
Best Local Similarity 99.5%; Pred. No. 6.9e-54;  
Matches 213; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 ATAAAGGCTAGGCTGAGAGAGTGTCTGCGACAGTCCACTACTTTTTCAGAGTGAATCC 60  
DB 274 ATAAAGGCTAGGCTGAGAGAGTGTCTGCGACAGTCCACTACTTTTTCAGAGTGAATCC 333  
QY 61 GTTGTCCCAAGGCTTCCAGAGCGCAACTGTGCGGCTGACGACCCGCGCTCGAGTTT 120  
DB 334 GTTGTCCCAAGGCTTCCAGAGCGCAACTGTGCGGCTGACGACCCGCGCTCGAGTTT 393  
QY 121 CCGGGGTCCGAGAGAGAGAGCTCTTCTCGCGGATCCAGTGTTCGTTCCAGCCCCCA 180  
DB 394 CCGGGGTCCGAGAGAGAGAGCTCTTCTCGCGGATCCAGTGTTCGTTCCAGCCCCCA 453  
QY 181 TCTCAGAGCCGAGCCGACAGAGAGAGGAAACCG 214  
DB 454 TCTCAGAGCCGAGCCGACAGAGAGAGGAAACCG 487

RESULT 15  
ADM02338  
ID ADM02338 standard; cDNA; 1903 BP.  
XX  
AC ADM02338;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE Human cDNA of the invention SEQ ID NO:1023.  
XX  
KW ss; gene; human; gene therapy; diagnostic marker; pharmaceutical.  
XX  
OS Homo sapiens.  
XX  
PN EP1347046-A1.  
XX  
PD 24-SEP-2003.  
XX  
PF 12-APR-2002; 2002EP-00008400.  
XX  
PR 22-MAR-2002; 2002JP-00137785.  
XX  
PA (REAS-) RES ASSOC BIOTECHNOLOGY.  
XX  
PI Isogai T, Sugiyama T, Otsuki T, Wakamatsu A, Sato H, Ishii S;  
PI Yamamoto J, Isono Y, Hio Y, Otsuka K, Nagai K, Irie R, Tamechika I;  
PI Seki N, Yoshikawa T, Otsuka M, Nagahara K, Masuno Y;  
XX  
DR MPI; 2003-723558/69.  
XX  
DR P-PSDB; ADM04781.  
XX  
PT New polynucleotides and polypeptides are useful in gene therapy, for  
PT developing a diagnostic marker or medicines for regulating their  
PT expression and activity, or as a target of gene therapy.  
XX  
XX Claim 1; SEQ ID NO 1023; 305pp; English.  
XX

CC The invention relates to a novel human polynucleotide and the encoded  
 CC polypeptide. A polynucleotide of the invention may have a use in gene  
 CC therapy. An oligonucleotide of the invention ADM06202-ADM06773 is useful  
 CC as a primer for synthesizing the polynucleotide or as a probe for  
 CC detecting the polynucleotide. The polynucleotides ADM0316-ADM03758 are  
 CC useful in gene therapy, for developing a diagnostic marker or medicines  
 CC for regulating their expression and activity, or as a target of gene  
 CC therapy. The proteins ADM03759-ADM06201 encoded by the polynucleotides  
 CC are useful as pharmaceutical agents. The present sequence represents a  
 CC cDNA sequence of the invention.

XX  
 SQ Sequence 1903 BP; 425 A; 531 C; 590 G; 357 T; 0 U; 0 Other;

Query Match 97.9%; Score 210.4; DB 11; Length 1903;

Best Local Similarity 99.5%; Pred. No. 2.6e-53;

Matches 211; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY	3 AACGGCTAGCCTGAGAGAGCTGCTGGCGACAGTCACCTTTTGGAGAGTGACTCCCGT	62
DB	1 AACGGCTAGCCTGAGAGAGCTGCTGGCGACAGTCACCTTTTGGAGAGTGACTCCCGT	60
QY	63 TGTCCCAAGGCTTCCGAGAGCGAAGCTGTGCGGCTGACAGGACCGGCGGTGAGTTTC	122
DB	61 TGTCCCAAGGCTTCCGAGAGCGAAGCTGTGCGGCTGACAGGACCGGCGGTGAGTTTC	120
QY	123 GCGGTCCGGAAGAGCCGAGCTTTCTCGGGATCCAGTGTTCGTTTCCAGCCCCCAATC	182
DB	121 GCGGTCCGGAAGAGCCGAGCTTTCTCGGGATCCAGTGTTCGTTTCCAGCCCCCAATC	180
QY	183 TCAGAGCCGAGCCGACAGAGAGAGGAGACCG	214
DB	181 TCAGAGCCGAGCCGACAGAGAGAGGAGACCG	212

Search completed: February 11, 2005, 08:17:28  
 Job time : 224 secs

235

Query Match	100.0%;	Score 215;	DB 1;	Length 533;
Best Local Similarity	100.0%;	Pred. No. 5;	6e-57;	
Matches 215;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0
Qy	1	ATAACGGCTAGCGCTGAGAGAGCTGCTGCGACAGCTCCACTTCTTTTTCGAGAGAGCACTCCC	60	
Db	235	ATAACGGCTAGCGCTGAGAGAGCTGCTGCGACAGCTCCACTTCTTTTTCGAGAGAGCACTCCC	234	

[illegible]

## RESULT 2

```

US-08-539-825-2
Sequence 2, Application US/08599825
Patent No. 5733745
GENERAL INFORMATION:
APPLICANT: KOWALSKI, JACEK
APPLICANT: GILBERT, SCOTT
APPLICANT: ZAMB, TIMOTHY J.
TITLE OF INVENTION: BOVINE HEAT SHOCK PROMOTER AND USBS
TITLE OF INVENTION: THEREOF
NUMBER OF SEQUENCES: 2
CORRESPONDENCE ADDRESS:
ADDRESSEE: ROBERTA L. ROBINS
STREET: 285 HAMILTON AVENUE, SUITE 200
CITY: PALO ALTO
STATE: CALIFORNIA
COUNTRY: UNITED STATES OF AMERICA
ZIP: 94301
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/539,825
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: ROBINS, ROBERTA L.
REGISTRATION NUMBER: 33,308
REFERENCE/DOCKET NUMBER: 9001-0003.01
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 327-3400
TELEFAX: (415) 327-3231
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 533 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-539-825-2

```

Query Match	100.0%;	Score 215;	DB 1;	Length 533;
Best Local Similarity	100.0%;	Pred. No. 5.6e-57;		
Matches 215;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0

QY	1	ATTAACGGCGTAGCGCTGAGAGAGCTGCTGAGACAGTCCCACTACCTTTTTCGAAAGGAGACCTCCC	60
Db	235	ATTAACGGCGTAGCGCTGAGAGAGCTGCTGAGACAGTCCCACTACCTTTTTCGAAAGGAGACCTCCC	2394
QY	61	GTTGTGCCAAGGCTTCCCAAGAGGAAACCTGTGCGGCTGACAGGCAACCGGCGCGTTCGAGTTT	120
Db	295	GTTGTGCCAAGGCTTCCCAAGAGGAAACCTGTGCGGCTGACAGGCAACCGGCGCGTTCGAGTTT	354
QY	121	CTGGCGTCCGGAAGGACCGAGCTCTTCTCGCGGATCCAGTTCCTGTTTCCAGCCGCCCA	180
Db	355	CTGGCGTCCGGAAGGACCGAGCTCTTCTCGCGGATCCAGTTCCTGTTTCCAGCCGCCCA	414

QY 181 TCTGAGCGCGAGCCGACAGAGAGCAGGGAACTCC 215  
D5 415 TCTGAGCGCGAGCCGACAGAGAGCAGGGAACTCC 449

### RESULT 3

```

US-09-048-488-2
/ Sequence 2, Application US/0904848
/ Patent No. 5981224
/
GENERAL INFORMATION:
/ APPLICANT: KOMALSKI, JACEK
/ APPLICANT: GILBERT, SCOTT
/ APPLICANT: ZAMB, TIMOTHY J.
/ TITLE OF INVENTION: BOVINE HEAT SHOCK PROMOTER AND USES
/ TITLE OF INVENTION: THEREOF
/ NUMBER OF SEQUENCES: 2
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: ROBERTA L. ROBINS
/ STREET: 635 BRYANT STREET
/ CITY: PALO ALTO
/ STATE: CALIFORNIA
/ COUNTRY: UNITED STATES OF AMERICA
/ ZIP: 94301
/
COMPUTER READABLE FORM:
/ MEDIUM TYPE: floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/
CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/048,488
/ FILING DATE:
/
CLASSIFICATION:
/
PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US/07/975,719
/ FILING DATE: 1992-11-13
/
ATTORNEY/AGENT INFORMATION:
/ NAME: ROBINS, ROBERTA L.
/ REGISTRATION NUMBER: 33,208
/ REFERENCE/DOCKET NUMBER: 9001-0003
/
TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (415) 617-8999
/ TELEFAX: (415) 327-3331
/
INFORMATION FOR SEQ ID NO.: 2:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 533 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/
MOLECULE TYPE: DNA (genomic)
/
US-09-048-488-2

```

Query Match	100.0%;	Score 215;	DB 2;	Length 533;
Best Local Similarity	100.0%;	Pred. No. 5.6e-57;		
Matches 215; Conservative	0;	Mismatches	0;	Indels 0; Gaps 0

Qy	1	ATACGGCTAGACCTAGAGAGCTGCTGCACAGTCCACTACCTTTTGGAGGTACCTCC	60
Db	235	ATACGGCTAGACCTAGAGAGCTGCTGCACAGTCCACTACCTTTTGGAGGTACCTCC	29
Qy	61	GTGTGCCAAGGCTTCCAGACGAACTGTGCGGCTGCAGACACCGCGGTGCACTTT	120
Db	295	GTGTGCCAAGGCTTCCAGACGAACTGTGCGGCTGCAGACACCGCGGTGCACTTT	35
Qy	121	CGGCGCTCCGGAAGACCGAGCTCTTCTCGCGGATCCAGTGTTCGTTTCCAGCCCCAA	180
Db	355	CGGCGCTCCGGAAGACCGAGCTCTTCTCGCGGATCCAGTGTTCGTTTCCAGCCCCAA	414
Qy	181	TCTCAGAGCCGAGCCGACAGAGACGAGGAAACCGC	215
Db	415	TCTCAGAGCCGAGCCGACAGAGACGAGGAAACCGC	449

## RESULT 4

US-08-955-565A-1  
; Sequence 1, Application US/08955565A  
; Patent No. 631388  
; GENERAL INFORMATION:  
; APPLICANT: Malkovsky, Miroslav  
; APPLICANT: Wells, Andrew  
; TITLE OF INVENTION: Immune Response Enhancer Therapy  
; FILE REFERENCE: MARF-02625  
; CURRENT APPLICATION NUMBER: US/08/955,565A  
; CURRENT FILING DATE: 1997-10-17  
; NUMBER OF SEQ ID NOS: 6  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1  
; LENGTH: 2691  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-08-955-565A-1

Query Match 100.0%; Score 215; DB 3; Length 2691;  
Best Local Similarity 100.0%; Pred. No. 8.7e-57;  
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATAAAGGCTAGGCTTGAAGAGCTGCTCCGACAGTCCACTACCTTTTTCGAGAGTGAAGTCCC 60  
DB 274 ATAAAGGCTAGGCTTGAAGAGCTGCTCCGACAGTCCACTACCTTTTTCGAGAGTGAAGTCCC 333  
QY 61 GTTGTCCCAAGGCTTCCGAGCGAAGCTGTGCGGCTGCGAGGACCGCGCGCTCGAGTTT 120  
DB 334 GTTGTCCCAAGGCTTCCGAGCGAAGCTGTGCGGCTGCGAGGACCGCGCGCTCGAGTTT 393  
QY 121 CCGGGCTCCGGAAGAACCGAGCTCTTCTGCGGATCCAGTGTTCGGTTTCCAGCCCCCA 180  
DB 394 CCGGGCTCCGGAAGAACCGAGCTCTTCTGCGGATCCAGTGTTCGGTTTCCAGCCCCCA 453  
QY 181 TCTCAGAGCCGAGCCGAG 215  
DB 454 TCTCAGAGCCGAGCCGAG 488

## RESULT 5

US-09-919-039-144  
; Sequence 144, Application US/09919039  
; Patent No. 6727066  
; GENERAL INFORMATION:  
; APPLICANT: Kaser, Matthew R.  
; TITLE OF INVENTION: GENES EXPRESSED IN TREATED HUMAN C3A LIVER CELL CULTURES  
; FILE REFERENCE: PA-0035 US  
; CURRENT FILING DATE: 2002-09-09  
; PRIOR APPLICATION NUMBER: 60/222,113  
; PRIORITY FILING DATE: 2000-07-26  
; NUMBER OF SEQ ID NOS: 401  
; SOFTWARE: PERL Program  
; SEQ ID NO 144  
; LENGTH: 2412  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: misc feature  
; OTHER INFORMATION: Incyte ID No. 6727066 242010.16  
US-09-919-039-144

Query Match 89.0%; Score 191.4; DB 4; Length 2412;  
Best Local Similarity 99.0%; Pred. No. 1.7e-49;  
Matches 203; Conservative 0; Mismatches 1; Indels 1; Gaps 1;

QY 11 GCGTGAAGAGCTGCTGCGAGCACTACCTTTTTCGAGAGTGAAGTCCCGTTGTCCTCAA 70  
DB 1 GCGTGAAGAGCTGCTGCGAGCACTACCTTTTTCGAGAGTGAAGTCCCGTTGTCCTCAA 60  
QY 71 GCGTTCCTCCAGAGAGCAAGCTGT- GCGGCTCCAGAGACCGCGCGCTCGAGTTTCCGCGCTCC 129  
DB 61 GCGTTCCTCCAGAGAGCAAGCTGTGCGGCTGCGAGGACCGGCGCTCGAGTTTCCGCGCTCC 120

QY 120 GGAAGAGCCGAGCTCTTCTCGCGAGTCCAGTGTTCGTTTCCAGCCCCCAATCTCAGAGC 189  
DB 121 GGAAGAGCCGAGCTCTTCTCGCGAGTCCAGTGTTCGTTTCCAGCCCCCAATCTCAGAGC 180  
QY 190 CGAGCCGACAG 214  
DB 181 CGAGCCGACAG 205

## RESULT 6

US-09-621-976-827  
; Sequence 827, Application US/09621976  
; Patent No. 6639063  
; GENERAL INFORMATION:  
; APPLICANT: Dumas Milne Edwards, J.B.  
; APPLICANT: Jodert, S.  
; APPLICANT: Giordano, J.Y.  
; TITLE OF INVENTION: ESTs and Encoded Human Proteins.  
; FILE REFERENCE: GENSET.054PR2  
; CURRENT APPLICATION NUMBER: US/09/621,976  
; CURRENT FILING DATE: 2000-07-21  
; NUMBER OF SEQ ID NOS: 19335  
; SOFTWARE: Patent.pm  
; SEQ ID NO 827  
; LENGTH: 420  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: CDS  
; LOCATION: 218..418  
US-09-621-976-827

Query Match 87.2%; Score 187.4; DB 4; Length 420;  
Best Local Similarity 97.7%; Pred. No. 1.8e-48;  
Matches 210; Conservative 1; Mismatches 2; Indels 2; Gaps 2;

QY 1 ATAAAGGCTAGGCTTGAAGAGCTGCTCCGACAGTCCACTACCTTTTTCGAGAGTGAAGTCCC 60  
DB 2 ATAAAGGCTAGGCTTGAAGAGCTGCTCCGACAGTCCACTACCTTTTTCGAGAGTGAAGTCCC 61  
QY 61 GTTGTCCCAAGGCTTCCGAGCGAAGCTGTGCGGCTGCGAGGACCGCGCGCTCGAGTTT 120  
DB 62 GTTGTCCCAAGGCTTCCGAGCGAAGCTGTGCGGCTGCGAGGACCGCGCGCTCGAGTTT 121  
QY 121 CCGGGCTCCGGAAGAACCGAGCTCTTCTGCGGATCCAGTGTTCGTTTCCAGCCCCCA 179  
DB 122 CCGGGCTCCGGAAGAACCGAGCTCTTCTGCGGATCCAGTGTTCGTTTCCAGCCCCCA 181  
QY 180 ATCTCAGAGCCGAGCCGACAG 214  
DB 182 ATCTCAGAGCCGAGCCGACATAG 215

## RESULT 7

US-09-919-039-145  
; Sequence 145, Application US/09919039  
; Patent No. 6727066  
; GENERAL INFORMATION:  
; APPLICANT: Kaser, Matthew R.  
; TITLE OF INVENTION: GENES EXPRESSED IN TREATED HUMAN C3A LIVER CELL CULTURES  
; FILE REFERENCE: PA-0035 US  
; CURRENT APPLICATION NUMBER: US/09/919,039  
; CURRENT FILING DATE: 2002-09-09  
; PRIOR APPLICATION NUMBER: 60/222,113  
; PRIORITY FILING DATE: 2000-07-28  
; NUMBER OF SEQ ID NOS: 401  
; SOFTWARE: PERL Program  
; SEQ ID NO 145  
; LENGTH: 2458  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
; FEATURE:

QY 11 GCGTGAAGAGCTGCTGCGAGCACTACCTTTTTCGAGAGTGAAGTCCCGTTGTCCTCAA 70  
DB 1 GCGTGAAGAGCTGCTGCGAGCACTACCTTTTTCGAGAGTGAAGTCCCGTTGTCCTCAA 60  
QY 71 GCGTTCCTCCAGAGAGCAAGCTGT- GCGGCTCCAGAGACCGCGCGCTCGAGTTTCCGCGCTCC 129  
DB 61 GCGTTCCTCCAGAGAGCAAGCTGTGCGGCTGCGAGGACCGGCGCTCGAGTTTCCGCGCTCC 120

```
/ NAME/KEY: misc.feature
/ OTHER INFORMATION: Incyte ID No. 6727066 1678695CBI
US-09-919-039-145

Query Match      72.9%; Score 156.8; DB 4; Length 2458;
Best Local Similarity 88.5%; Pred. No. 8.6e-39;
Matches 170; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

QY 11 GCGTGAAGAGCTGCTGCGAGCAGTCCACTACCTTTTTCGAGAGTACTCCCGTTGTCCTCA 70
DB 1 GCGTGAAGAGCTGCTGCGAGGCTCCGCTTCTGTTTCGAGAGTACTCCCGGCTCCAA 60
QY 71 GCGTTCCCGAGCGAACTGTGCGCTGCAAGCAGCGCGCTGAGTTTCCGCGCTCCG 130
DB 61 GCGTTCCCGAGCGAACTGTGCGCTGCAAGCAGCGCGCTGAGTTTCCGCGCTCC 120
QY 131 GAAGAGCAGAGCTCTTCTGCGGATCCAGTGTTCGTTTCCAGCCCCCAATCTCAGAGCC 190
DB 121 GAAGAGCAGAGCTCTTCTGCGGATCCAGTGTTCGTTTCCAGCCCCCAATCTCAGAGCG 180
QY 191 GAGCCGACAGAG 202
DB 181 GAGCCGACAGAG 192

RESULT 8
US-09-976-594-996
/ Sequence 996, Application US/09976594
/ Patent No. 6673549
/ GENERAL INFORMATION:
/ APPLICANT: Furness, Michael
/ APPLICANT: Buchdinder, Jenny
/ TITLE OF INVENTION: GENES EXPRESSED IN C3A LIVER CELL CULTURES TREATED WITH STEROIDS
/ FILE REFERENCE: PA-0041 US
/ CURRENT APPLICATION NUMBER: US/09/976,594
/ PRIOR FILING DATE: 2001-10-12
/ PRIOR APPLICATION NUMBER: 60/240,409
/ NUMBER OF SEQ ID NOS: 1143
/ SOFTWARE: PERL Program
/ SEQ ID NO 996
/ LENGTH: 1941
/ TYPE: DNA
/ ORGANISM: Homo sapiens
/ FEATURE:
/ NAME/KEY: misc.feature
/ OTHER INFORMATION: Incyte ID No. 6673549 242010.60
US-09-976-594-996

Query Match      46.1%; Score 99.2; DB 4; Length 1941;
Best Local Similarity 89.2%; Pred. No. 5.3e-21;
Matches 107; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 83 CGAAGCTGCGGCTGCGAGCAACCGCGGTGAGTTTCCGCGTCCGGAAGAGCCGAGC 142
DB 1 CGAAGCTGCGGCTGCGAGCAACCGCGGTGAGTTTCCGCGTCCGGAAGAGCTGAGC 60
QY 143 TCTTTCGCGGATCCAGTGTTCGTTTCCAGCCCCCAATCTCAGAGCCGAGCGAGAG 202
DB 61 TCTTTCGCGGATCCAGTGTTCGTTTCCAGCCCCCAATCTCAGAGCCGAGCGAGAG 120

RESULT 9
US-07-975-719-1
/ Sequence 1, Application US/07975719
/ Patent No. 5521084
/ GENERAL INFORMATION:
/ APPLICANT: KOMALSKI, JACEK
/ APPLICANT: GILBERT, SCOTT
/ APPLICANT: ZAMB, TIMOTHY J.
/ TITLE OF INVENTION: BOVINE HEAT SHOCK PROMOTER AND USES
/ TITLE OF INVENTION: THEREOF
/ NUMBER OF SEQUENCES: 2
```

```
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: ROBERTA L. ROBINS
/ STREET: 635 BRYANT STREET
/ CITY: PALO ALTO
/ STATE: CALIFORNIA
/ COUNTRY: UNITED STATES OF AMERICA
/ ZIP: 94301
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ FILING DATE: 19921113
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
/ NAME: ROBINS, ROBERTA L.
/ REGISTRATION NUMBER: 33,208
/ REFERENCE/DOCKET NUMBER: 9001-0003
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (415) 617-8999
/ TELEFAX: (415) 327-1331
/ INFORMATION FOR SEQ ID NO: 1:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 750 base pairs
/ TYPE: NUCLEIC ACID
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
US-07-975-719-1

Query Match      17.0%; Score 36.6; DB 1; Length 750;
Best Local Similarity 66.0%; Pred. No. 0.096;
Matches 68; Conservative 0; Mismatches 34; Indels 1; Gaps 1;

QY 101 GGCACCGCGCGCTCAGTTTCCGCGCTCCGGAAGAGCCGAGC-TTTCCTCGGAGATCCAG 159
DB 552 GGCACCGAGCGCTTCAAGTTTCCGCGCTCCGAAGAGCCGAGGCTTCTCGTCCGAGTCTTC 611
QY 160 TGTTCCGTTTCCAGCCCCCAATCTCAGAGCGCGAGCGAGAG 202
DB 612 TTCACCGATTTCAGGTTTGAAGCTTATTTCGAGCGGAGAAAG 654

RESULT 10
US-08-599-825-1
/ Sequence 1, Application US/08599825
/ Patent No. 5733745
/ GENERAL INFORMATION:
/ APPLICANT: KOMALSKI, JACEK
/ APPLICANT: GILBERT, SCOTT
/ APPLICANT: ZAMB, TIMOTHY J.
/ TITLE OF INVENTION: BOVINE HEAT SHOCK PROMOTER AND USES
/ TITLE OF INVENTION: THEREOF
/ NUMBER OF SEQUENCES: 2
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: ROBERTA L. ROBINS
/ STREET: 285 HAMILTON AVENUE, SUITE 200
/ CITY: PALO ALTO
/ STATE: CALIFORNIA
/ COUNTRY: UNITED STATES OF AMERICA
/ ZIP: 94301
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ FILING DATE:
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
```

```

; NAME: ROBINS, ROBERTA L.
; REGISTRATION NUMBER: 33,208
; REFERENCE/DOCKET NUMBER: 9001-0003.01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 327-3400
; TELEFAX: (415) 327-3231
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 750 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
;
US-08-599-825-1
;
Query Match
Best Local Similarity 17.0%; Score 36.6; DB 1; Length 750;
Matches 68; Conservative 0; Mismatches 34; Indels 1; Gaps 1;
;
QY 101 GGCACCGCGCGCTCGAGTTTCCGGCGTCCGGAAGACCGAGC-TCTTCTCGCGATCCAG 159
DB 552 GGCACCGAGCGCTTACGTTTTCGGGTTCGAAAGCCGAGCTTCTCGAGATCTTC 611
QY 160 TGTTCGTTTCCAGCCCCCAATCTCAGAGCCGAGCCGACAG 202
DB 612 TTCACCGATTTCAGGTTTGAAGCTTATTTCGAGCCGGAAG 654
;
RESULT 11
US-09-048-488-1
; Sequence 1, Application US/09048488
; Patent No. 5981224
; GENERAL INFORMATION:
; APPLICANT: KOMALSKI, JACEK
; APPLICANT: GILBERT, SCOTT
; APPLICANT: ZAMB, TIMOTHY J.
; TITLE OF INVENTION: BOVINE HEAT SHOCK PROMOTER AND USES
; TITLE OF INVENTION: THEREOF
; NUMBER OF SEQUENCES: 2
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ROBERTA L. ROBINS
; STREET: 635 BRYANT STREET
; CITY: PALO ALTO
; STATE: CALIFORNIA
; COUNTRY: UNITED STATES OF AMERICA
; ZIP: 94301
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/048,488
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/975,719
; FILING DATE: 1992-11-13
; ATTORNEY/AGENT INFORMATION:
; NAME: ROBINS, ROBERTA L.
; REGISTRATION NUMBER: 33,208
; REFERENCE/DOCKET NUMBER: 9001-0003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 617-8999
; TELEFAX: (415) 327-3231
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 750 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
;
US-09-048-488-1
```

```

Query Match
Best Local Similarity 17.0%; Score 36.6; DB 2; Length 750;
Matches 68; Conservative 0; Mismatches 34; Indels 1; Gaps 1;
;
QY 101 GGCACCGCGCGCTCGAGTTTCCGGCGTCCGGAAGACCGAGC-TCTTCTCGCGATCCAG 159
DB 552 GGCACCGAGCGCTTACGTTTTCGGGTTCGAAAGCCGAGCTTCTCGAGATCTTC 611
QY 160 TGTTCGTTTCCAGCCCCCAATCTCAGAGCCGAGCCGACAG 202
DB 612 TTCACCGATTTCAGGTTTGAAGCTTATTTCGAGCCGGAAG 654
;
RESULT 12
US-09-252-991A-11809/C
; Sequence 11809, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
; APPLICANT: Marc J. Rubenfield et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
; TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 107196.136
; CURRENT APPLICATION NUMBER: US/09/252,991A
; PRIOR FILING DATE: 1999-02-18
; PRIOR APPLICATION NUMBER: US 60/074,788
; PRIOR FILING DATE: 1998-02-18
; PRIOR APPLICATION NUMBER: US 60/094,190
; PRIOR FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 33142
; SEQ ID NO 11809
; LENGTH: 1074
; TYPE: DNA
; ORGANISM: Pseudomonas aeruginosa
;
US-09-252-991A-11809
;
Query Match
Best Local Similarity 15.6%; Score 33.6; DB 4; Length 1074;
Matches 57; Conservative 0; Mismatches 39; Indels 0; Gaps 0;
;
QY 82 GCGAAGCTGTGGCGCTGCAAGCGAGCGGCGCTTCGAGTTTCCGGCTCCGAAAGACCGAG 141
DB 828 GCGATCCTGTGGCGGTGAGCGCCGATCGCGCTTCGAGTTCCGCGCTTCGAGCGCTTCAG 769
QY 142 CTCTTCGCGGATCCAGGTTCGTTCCAGCCCC 177
DB 768 GAGATCGCCAGTCTGAGCTTCCAGCCGAGCCCC 733
;
RESULT 13
US-09-252-991A-11869/C
; Sequence 11869, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
; APPLICANT: Marc J. Rubenfield et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
; TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 107196.136
; CURRENT APPLICATION NUMBER: US/09/252,991A
; PRIOR FILING DATE: 1999-02-18
; PRIOR APPLICATION NUMBER: US 60/074,788
; PRIOR FILING DATE: 1998-02-18
; PRIOR APPLICATION NUMBER: US 60/094,190
; PRIOR FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 33142
; SEQ ID NO 11869
; LENGTH: 1320
; TYPE: DNA
; ORGANISM: Pseudomonas aeruginosa
;
US-09-252-991A-11869
;
Query Match
Best Local Similarity 15.6%; Score 33.6; DB 4; Length 1320;
Matches 59.4%; Pred. No. 0.95;
```

Matches 57; Conservative 0; Mismatches 39; Indels 0; Gaps 0;  
Qy 82 GCGAAGCTGTGCGGTGAGGACCGCGCGTGTGAGTTTCCGCGTCCGGAAGACCGAG 141  
Db 1103 GCGATCTGTGCGGTGAGGACCGCGCGTGTGAGTTTCCGCGTCCGGAAGACCGAG 1044  
Qy 142 CTCCTTCGCGGATCCAGTGTTCGTTTCCAGCCCC 177  
Db 1043 GAGATCGGCGAGTCCGTAGGCTTCCAGCCAGGCC 1008

RESULT 14  
US-09-313-294A-6467  
; Sequence 6467, Application US/09313294A  
; Patent No. 6476212  
; GENERAL INFORMATION:  
; APPLICANT: Lalgudi, Raghunath V.  
; APPLICANT: Ito, Laura Y.  
; APPLICANT: Sherman, Bradley K.  
; TITLE OF INVENTION: POLYNUCLEOTIDES AND POLYPEPTIDES DERIVED FROM CORN EAR  
; FILE REFERENCE: PL-0017 US  
; CURRENT APPLICATION NUMBER: US/09/313,294A  
; CURRENT FILING DATE: 1999-05-14  
; NUMBER OF SEQ ID NOS: 7600  
; SOFTWARE: PERL Program  
; SEQ ID NO 6467  
; LENGTH: 205  
; TYPE: DNA  
; ORGANISM: Zea mays  
; FEATURE:  
; NAME/KEY: misc\_feature  
; OTHER INFORMATION: Incyte ID No. 6476212 700351854H1  
; NAME/KEY: unsure  
; LOCATION: 31, 178, 202-203  
; OTHER INFORMATION: a, t, c, g, or other  
US-09-313-294A-6467

Query Match 15.1%; Score 32.4; DB 4; Length 205;  
Best Local Similarity 68.2%; Pred. No. 1.3;  
Matches 45; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

Qy 149 CCGGATCCAGTGTTCGTTTCCAGCCCCCAATCTCAGAGCCGCGGACGAGAGAGCAG 208  
Db 80 CACGAGCAAGAGATTCTGTCTGCATTATTACCGAGCCGCGGAGAGAGTCAAG 139  
Qy 209 GAACCG 214  
Db 140 CAACCG 145

RESULT 15  
US-09-902-540-4475/C  
; Sequence 4475, Application US/09902540  
; Patent No. 6833447  
; GENERAL INFORMATION:  
; APPLICANT: Goldman, Barry S.  
; APPLICANT: Hinkle, Gregory J.  
; APPLICANT: Slater, Steven C.  
; APPLICANT: Wiegand, Roger C.  
; TITLE OF INVENTION: Myxococcus xanthus Genome Sequences and Uses Thereof  
; FILE REFERENCE: 38-10(15849)B  
; CURRENT APPLICATION NUMBER: US/09/902,540  
; CURRENT FILING DATE: 2001-07-10  
; PRIOR APPLICATION NUMBER: 60/217,883  
; PRIOR FILING DATE: 2000-07-10  
; NUMBER OF SEQ ID NOS: 16825  
; SEQ ID NO 4475  
; LENGTH: 1728  
; TYPE: DNA  
; ORGANISM: Myxococcus xanthus  
US-09-902-540-4475

Query Match 15.1%; Score 32.4; DB 4; Length 1728;

Best Local Similarity 50.0%; Pred. No. 2.4;  
Matches 81; Conservative 0; Mismatches 81; Indels 0; Gaps 0;

Qy 16 AGAAGCTGTGAGACATCCACTTCTTTGAGAGAGACTCCGTTGTCCAAAGCTT 75  
Db 1628 AGAAGCTGTGAGACATCCACTTCTTTGAGAGAGACTCCGTTGTCCAAAGCTT 1569  
Qy 76 CCCAGAGCGAAGCTGTGCGGTGAGGACCGCGCGTGTGAGTTTCCGCGTCCGAAG 135  
Db 1568 GCTGCGCGCGCGGTGCGGACCGCGCTTCACCCATGAGACCGTGTGATGCGGTCAAG 1509  
Qy 136 ACCGAGCTTCTCGCGGATCCAGTGTTCGTTTCCAGCCCC 177  
Db 1508 GCCAGTGAATTTCCGGTTCGAACGGGTCCAGCGCCAGCGCC 1467

Search completed: February 11, 2005, 09:04:16  
Job time : 89 secs



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using SW model

Run on: February 11, 2005, 08:35:16 ; Search time 259 Seconds  
(without alignments)  
4898.065 Million cell updates/sec

Title: US-09-936-506-1

Perfect score: 215  
1 ataacgcctagcctcgagag.....gacagagacgaggaaccgc 215

Scoring table: IDENTITY NUC  
Gapop 10.0, Gapext 1.0

Searched: 5378673 seqs, 2950229984 residues

Total number of hits satisfying chosen parameters: 10757346

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :

Published Applications NA: \*  
1: /cgn2\_6/ptodata/1/pubpna/US07\_PUBCOMB.seq: \*  
2: /cgn2\_6/ptodata/1/pubpna/PCT\_NEW\_PUB.seq: \*  
3: /cgn2\_6/ptodata/1/pubpna/US06\_NEW\_PUB.seq: \*  
4: /cgn2\_6/ptodata/1/pubpna/US06\_PUBCOMB.seq: \*  
5: /cgn2\_6/ptodata/1/pubpna/US07\_NEW\_PUB.seq: \*  
6: /cgn2\_6/ptodata/1/pubpna/PCTUS\_PUBCOMB.seq: \*  
7: /cgn2\_6/ptodata/1/pubpna/US08\_NEW\_PUB.seq: \*  
8: /cgn2\_6/ptodata/1/pubpna/US08\_PUBCOMB.seq: \*  
9: /cgn2\_6/ptodata/1/pubpna/US09\_PUBCOMB.seq: \*  
10: /cgn2\_6/ptodata/1/pubpna/US09\_PUBCOMB.seq: \*  
11: /cgn2\_6/ptodata/1/pubpna/US09C\_PUBCOMB.seq: \*  
12: /cgn2\_6/ptodata/1/pubpna/US09\_NEW\_PUB.seq: \*  
13: /cgn2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq: \*  
14: /cgn2\_6/ptodata/1/pubpna/US10B\_PUBCOMB.seq: \*  
15: /cgn2\_6/ptodata/1/pubpna/US10C\_PUBCOMB.seq: \*  
16: /cgn2\_6/ptodata/1/pubpna/US10D\_PUBCOMB.seq: \*  
17: /cgn2\_6/ptodata/1/pubpna/US10E\_PUBCOMB.seq: \*  
18: /cgn2\_6/ptodata/1/pubpna/US10F\_PUBCOMB.seq: \*  
19: /cgn2\_6/ptodata/1/pubpna/US10F\_NEW\_PUB.seq: \*  
20: /cgn2\_6/ptodata/1/pubpna/US11\_NEW\_PUB.seq: \*  
21: /cgn2\_6/ptodata/1/pubpna/US60\_NEW\_PUB.seq: \*  
22: /cgn2\_6/ptodata/1/pubpna/US60\_PUBCOMB.seq: \*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	214	99.5	2732	US-10-335-053-291	Sequence 291, App
2	213.4	99.3	549	US-10-346-359-1	Sequence 1, Appl
3	210.4	97.9	1903	US-10-178-260A-1023	Sequence 1023, App
4	195	90.7	2387	US-10-172-118-1144	Sequence 1144, App
5	195	90.7	2387	US-10-342-887-1144	Sequence 1144, App
6	191.4	89.0	2412	US-09-919-039-144	Sequence 144, App
7	163.6	76.1	504	US-10-029-386-6557	Sequence 6557, App
8	158.2	73.6	286	US-10-425-115-89981	Sequence 89981, App
9	156.8	72.9	2458	US-09-919-039-145	Sequence 145, App
10	156.8	72.9	2513	US-10-335-053-290	Sequence 290, App
11	156.4	72.7	2771	US-10-027-632-111980	Sequence 111980, App

C	12	156.4	72.7	2771	17	US-10-027-632-111980	Sequence 111980, App
C	13	145.2	67.5	595	18	US-10-363-345A-17429	Sequence 17429, App
C	14	145.2	67.5	595	18	US-10-363-345A-17430	Sequence 17430, App
C	15	145.2	67.5	596	18	US-10-363-345A-20731	Sequence 20731, App
C	16	145.2	67.5	596	18	US-10-363-345A-20732	Sequence 20732, App
C	17	145.2	67.5	9899	15	US-10-311-455-2415	Sequence 2415, App
C	18	145.2	67.5	3673778	16	US-10-312-841-17431	Sequence 2, Appl
C	19	134	62.3	595	18	US-10-363-345A-17431	Sequence 17431, App
C	20	134	62.3	595	18	US-10-363-345A-17432	Sequence 17432, App
C	21	134	62.3	596	18	US-10-363-345A-20729	Sequence 20729, App
C	22	134	62.3	9899	15	US-10-363-345A-20730	Sequence 20730, App
C	23	134	62.3	9899	15	US-10-311-455-2416	Sequence 2416, App
C	24	134	62.3	3673778	16	US-10-312-841-17431	Sequence 1, Appl
C	25	116.6	54.2	2460	18	US-10-370-715B-21	Sequence 21, Appl
C	26	103.4	48.1	583	18	US-10-363-345A-17425	Sequence 17425, App
C	27	103.4	48.1	583	18	US-10-363-345A-17426	Sequence 17426, App
C	28	99.6	46.3	583	18	US-10-363-345A-17427	Sequence 17427, App
C	29	99.6	46.3	583	18	US-10-363-345A-17428	Sequence 17428, App
C	30	89.2	41.5	584	18	US-10-363-345A-20735	Sequence 20735, App
C	31	89.2	41.5	584	18	US-10-363-345A-20736	Sequence 20736, App
C	32	83.8	39.0	584	18	US-10-363-345A-20733	Sequence 20733, App
C	33	83.8	39.0	584	18	US-10-363-345A-20734	Sequence 20734, App
C	34	58	27.0	939	16	US-10-029-386-20724	Sequence 20724, App
C	35	38.4	17.9	2636	13	US-10-002-600-95	Sequence 95, Appl
C	36	34.2	15.9	2940917	17	US-10-027-632-174763	Sequence 174763, App
C	37	34.2	15.9	2940917	17	US-10-027-632-174763	Sequence 174763, App
C	38	32.8	15.3	1473	17	US-10-282-122A-14406	Sequence 14406, App
C	39	32.4	15.1	2261	17	US-10-389-566-273	Sequence 273, App
C	40	32.2	15.0	7789	17	US-10-333-314-38	Sequence 37, Appl
C	41	32.2	15.0	9698	17	US-10-210-130-37	Sequence 37, Appl
C	42	32.2	15.0	9807	17	US-10-379-381-1	Sequence 1, Appl
C	43	32.2	15.0	9930	17	US-10-210-130-33	Sequence 33, Appl
C	44	32.2	15.0	10122	17	US-10-210-130-35	Sequence 35, Appl
C	45	32.2	15.0	62805	17	US-10-379-381-3	Sequence 3, Appl

## ALIGNMENTS

RESULT 1  
US-10-335-053-291  
; Sequence 291, Application US/10335053  
; Publication No. US20040241653A1  
; GENERAL INFORMATION:  
; APPLICANT: Quark Biotech, Inc.  
; TITLE OF INVENTION: Methods for identifying marker genes for cancer  
; FILE REFERENCE: 68733-A, 070/US1  
; CURRENT APPLICATION NUMBER: US/10/335,053  
; PRIOR FILING DATE: 2003-03-27  
; PRIOR APPLICATION NUMBER: 60/345,317  
; PRIOR FILING DATE: 2001-12-31  
; NUMBER OF SEQ ID NOS: 319  
; SOFTWARE: Patencin version 3.2  
; SEQ ID NO 291  
; LENGTH: 2732  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-335-053-291

Query Match 99.5%; Score 214; DB 18; Length 2732;  
Best Local Similarity 100.0%; Pred. No. 2.4e-60;  
Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	ATTAAGGCTAGCGTCTGAGAGCTGCTGCACAGTCCACATCACTTTTCCAGAGTACCTCC	60
DB	274	ATTAAGGCTAGCGTCTGAGAGCTGCTGCACAGTCCACATCACTTTTCCAGAGTACCTCC	333
QY	61	GTTGTCCTCAAGGCTTCCAGAGCTGCTGCAGGCTGAGGACACCGGCGCTCAGATT	120
DB	334	GTTGTCCTCAAGGCTTCCAGAGCTGCTGCAGGCTGAGGACACCGGCGCTCAGATT	393
QY	121	CCGAGGCTCCGAGAGACCGAGCTCTTCTCGCGATTCAGATGTTCCGTTTCCAGCCCA	180

Db 394 CCGGCGCTCCGAGAGACCGAGCTCTTCTCCGCGATCCAGTGTTCGGTTCCAGCCCCCA 453

Qy 181 TCTCAGAGCCGAGCCGACAGAGAGCAGGGAACCG 214

Db 454 TCTCAGAGCCGAGCCGACAGAGAGCAGGGAACCG 487

## RESULT 2

US-10-348-359-1.  
; Sequence 1, Application US/10348359  
; Publication No. US20040018178A1  
; GENERAL INFORMATION:  
; APPLICANT: WEST, MICHAEL  
; TITLE OF INVENTION: STEM CELL-DERIVED ENDOTHELIAL CELLS MODIFIED TO DISRUPT  
; FILE REFERENCE: 100375, 54374US  
; CURRENT APPLICATION NUMBER: US/10/348,359  
; CURRENT FILING DATE: 2003-01-22  
; PRIOR APPLICATION NUMBER: 60/349,345  
; PRIOR FILING DATE: 2002-01-22  
; NUMBER OF SEQ ID NOS: 6  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO: 1  
; LENGTH: 549  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-348-359-1

Query Match 99.3%; Score 213.4; DB 17; Length 549;  
Best Local Similarity 99.5%; Pred. No. 3,4e-60;  
Matches 214; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 ATAAAGCGTAGCGCTGAGAGAGCTGCTGCGACAGTCCACTACCTTTTCGAGAGTGACTCCC 60

Db 269 ATAAAGCGTAGCGCTGAGAGAGCTGCTGCGACAGTCCACTACCTTTTCGAGAGTGACTCCC 328

Qy 61 GTTGTCCTCCAGGCTTCCAGAGCGAACTGTGCGGCTGAGAGACCGCGCGCTCGAGTTT 120

Db 329 GTTGTCCTCCAGGCTTCCAGAGCGAACTGTGCGGCTGAGAGACCGCGCGCTCGAGTTT 388

Qy 121 CCGGCGCTCCGAGAGAGCAGAGCTCTTCTGCGGATTCAGTGTTCGAGAGTGACTCCC 180

Db 389 CCGGCGCTCCGAGAGAGCAGAGCTCTTCTGCGGATTCAGTGTTCGAGAGTGACTCCC 448

Qy 181 TCTCAGAGCCGAGCCGACAGAGAGCAGGGAACCGC 215

Db 449 TCTCAGAGCCGAGCCGACAGAGAGCAGGGAACCGC 483

## RESULT 3

US-10-108-260A-1023  
; Sequence 1023, Application US/10108260A  
; Publication No. US20040005560A1  
; GENERAL INFORMATION:  
; APPLICANT: HELIX RESEARCH INSTITUTE  
; TITLE OF INVENTION: NO. US20040005560A1e1 full length cDNA  
; FILE REFERENCE: H1-A0106  
; CURRENT APPLICATION NUMBER: US/10/108,260A  
; CURRENT FILING DATE: 2002-03-27  
; NUMBER OF SEQ ID NOS: 5458  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO: 1023  
; LENGTH: 1903  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-108-260A-1023

Query Match 97.9%; Score 210.4; DB 17; Length 1903;  
Best Local Similarity 99.5%; Pred. No. 3,6e-59;  
Matches 211; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3 AACGGCTAGCGTAGAGAGCTGCTGCGACAGTCCACTTCTTTTCGAGAGTGACTCCGCT 62

Db 1 AACGGCTAGCGTAGAGAGAGCTGCTGCGACAGTCCACTTCTTTTCGAGAGTGACTCCGCT 60

Qy 63 TGTCCAAAGGCTTCCAGAGCGAACTGTGCGCTGAGAGACCGCGCGTTCGAGTTTCC 122

Db 61 TGTCCAAAGGCTTCCAGAGCGAACTGTGCGCTGAGAGACCGCGCGTTCGAGTTTCC 120

Qy 123 GCGCTCCGAGAGAGACCGAGCTTCTCCGCGATCCAGTGTTCGTTTCCAGCCCCCAATC 182

Db 121 GCGCTCCGAGAGAGACCGAGCTTCTCCGCGATCCAGTGTTCGTTTCCAGCCCCCAATC 180

Qy 183 TCAGAGCCGAGCCGACAGAGAGCAGGGAACCG 214

Db 181 TCAGAGCCGAGCCGACAGAGAGCAGGGAACCG 212

## RESULT 4

US-10-172-118-1144  
; Sequence 1144, Application US/10172118  
; Publication No. US20030224374A1  
; GENERAL INFORMATION:  
; APPLICANT: Dai, Hongyue  
; APPLICANT: Dai, Hongyue  
; APPLICANT: He, Yundong  
; APPLICANT: Linsley, Peter  
; APPLICANT: Mao, Mao  
; APPLICANT: Roberts, Chris  
; APPLICANT: Van 't Veer, Laura  
; APPLICANT: Van de Vijver, Marc  
; APPLICANT: Bernards, Rene  
; TITLE OF INVENTION: Diagnosis and Prognosis of Breast Cancer Patients  
; FILE REFERENCE: 9301-175-999  
; CURRENT APPLICATION NUMBER: US/10/172,118  
; CURRENT FILING DATE: 2002-06-14  
; PRIOR APPLICATION NUMBER: 60/380,770  
; PRIOR FILING DATE: 2002-05-14  
; NUMBER OF SEQ ID NOS: 2699  
; SEQ ID NO: 1144  
; LENGTH: 2387  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
; PUBLICATION INFORMATION:  
; DATABASE ACCESSION NUMBER: NM\_005345  
; DATABASE ENTRY DATE: 2001-06-18  
US-10-172-118-1144

Query Match 90.7%; Score 195; DB 17; Length 2387;  
Best Local Similarity 100.0%; Pred. No. 4,2e-54;  
Matches 195; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 20 GCTGCTGGACAGTCCACTTCTTTTCGAGAGTACTCCGTTGTCCCAAGGCTTCCCA 79

Db 1 GCTGCTGGACAGTCCACTTCTTTTCGAGAGTACTCCGTTGTCCCAAGGCTTCCCA 60

Qy 80 GAGCGAACCCTGTGCGGCTGCGAGGACCGCGCGCTGAGATTTCCGCGCTCCGGAAGAACCG 139

Db 61 GAGCGAACCCTGTGCGGCTGCGAGGACCGCGCGCTGAGATTTCCGCGCTCCGGAAGAACCG 120

Qy 140 AGCTCTTCTCGCGAGTCCAGTGTTCGTTTCCAGGCCCCCAATTCAGAGCCGAGCCGACA 199

Db 121 AGCTCTTCTCGCGAGTCCAGTGTTCGTTTCCAGGCCCCCAATTCAGAGCCGAGCCGACA 180

Qy 200 GAGAGCAGGGAACCG 214

Db 181 GAGAGCAGGGAACCG 195

## RESULT 5

US-10-342-887-1144  
; Sequence 1144, Application US/10342887  
; Publication No. US20040058340A1  
; GENERAL INFORMATION:  
; APPLICANT: Dai, Hongyue  
; APPLICANT: He, Yundong  
; APPLICANT: Linsley, Peter S.

APPLICANT: Mao, Mao  
APPLICANT: Roberts, Christopher J.  
APPLICANT: Van 't Veer, Laura Johanna  
APPLICANT: Van de Vijver, Marc J.  
APPLICANT: Bernards, Rene  
TITLE OF INVENTION: Diagnosis and Prognosis of Breast Cancer Patients  
FILE REFERENCE: 9301-188-999  
CURRENT APPLICATION NUMBER: US/10/342,887  
CURRENT FILING DATE: 2003-01-15  
PRIOR APPLICATION NUMBER: 60/298,918  
PRIOR FILING DATE: 2001-06-18  
PRIOR APPLICATION NUMBER: 60/380,710  
PRIOR FILING DATE: 2002-05-14  
PRIOR APPLICATION NUMBER: 10/172,118  
PRIOR FILING DATE: 2002-06-14  
NUMBER OF SEQ ID NOS: 2699  
SEQ ID NO 1144  
LENGTH: 2387  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-342-887-1144

Query Match 90.7%; Score 195; DB 17; Length 2387;  
Best Local Similarity 100.0%; Pred. No. 4.2e-54;  
Matches 195; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 20 GCTGCTGCGACAGTCCACTACTCTTTTCGAGAGTGAATCCGCTTGTCCCAAGGCTTCCCA 79  
DB 1 GCTGCTGCGACAGTCCACTACTCTTTTCGAGAGTGAATCCGCTTGTCCCAAGGCTTCCCA 60  
OY 80 GAGCGAACCTGTGCGGCTGCGAGCAACCGCGCGTGAATTTCCGCGCTCGGAGAACCG 139  
DB 61 GAGCGAACCTGTGCGGCTGCGAGCAACCGCGCGTGAATTTCCGCGCTCGGAGAACCG 120  
OY 140 AGCTTCTTCGCGGATCCAGTGTTCGCTTTCAGAGCCCCCAATCTCAGAGCCGAGCCGACA 199  
DB 121 AGCTTCTTCGCGGATCCAGTGTTCGCTTTCAGAGCCCCCAATCTCAGAGCCGAGCCGACA 180  
OY 200 GAGAGCAGGAGAACCG 214  
DB 181 GAGAGCAGGAGAACCG 195

RESULT 6  
US-09-919-039-144  
Sequence 144, Application US/09919039  
Publication No. US20030108871A1  
GENERAL INFORMATION:  
APPLICANT: Kaser, Matthew R.  
TITLE OF INVENTION: GENES EXPRESSED IN TREATED HUMAN C3A LAYER CELL CULTURES  
FILE REFERENCE: PA-0035 US  
CURRENT APPLICATION NUMBER: US/09/919,039  
CURRENT FILING DATE: 2002-09-09  
PRIOR APPLICATION NUMBER: 60/222,113  
PRIOR FILING DATE: 2000-07-28  
NUMBER OF SEQ ID NOS: 401  
SOFTWARE: PERL Program  
SEQ ID NO 144  
LENGTH: 2412  
TYPE: DNA  
ORGANISM: Homo sapiens  
FEATURE:  
NAME/KEY: misc feature  
OTHER INFORMATION: Incyte ID No. US20030108871A1 242010.16  
US-09-919-039-144

Query Match 89.0%; Score 191.4; DB 10; Length 2412;  
Best Local Similarity 99.0%; Pred. No. 6.4e-53;  
Matches 203; Conservative 0; Mismatches 1; Indels 1; Gaps 1;

OY 11 GCTTGAAGAGCTGCTGCGACAGTCCACTACTCTTTTCGAGAGTGAATCCGCTTGTCCCA 70  
DB 1 GCTTGAAGAGCTGCTGCGACAGTCCACTACTCTTTTCGAGAGTGAATCCGCTTGTCCCA 60

OY 71 GGTCTCCAGAGCGAAGCTGT-GCGGCTGCGAGGACCGGCGGCTGAGTTTCCGCGTCC 129  
DB 61 GGTCTCCAGAGCGAAGCTGTGCGGCTGCGAGGACCGGCGGCTGAGTTTCCGCGTCC 120  
OY 130 GGAAGACCGAGCTTCTTCGCGGATCCAGTGTTCGCTTTCAGAGCCCCCAATCTCAGAGC 189  
DB 121 GGAAGACCGAGCTTCTTCGCGGATCCAGTGTTCGCTTTCAGAGCCCCCAATCTCAGAGC 180  
OY 190 CGAGCGGACGAGAGCAGGAGAACCG 214  
DB 181 GAGCGCGACGAGAGCAGGAGAACCG 205

RESULT 7  
US-10-029-386-6557/C  
Sequence 6557, Application US/10029386  
Publication No. US20030194704A1  
GENERAL INFORMATION:  
APPLICANT: Penn, Sharon G.  
APPLICANT: Rank, David R.  
APPLICANT: Hanzel, David K.  
TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G  
FILE REFERENCE: AEOICA-X-2  
CURRENT APPLICATION NUMBER: US/10/029,386  
CURRENT FILING DATE: 2001-12-20  
NUMBER OF SEQ ID NOS: 34288  
SOFTWARE: Annomax Sequence Listing Engine vers. 1.1  
SEQ ID NO 6557  
LENGTH: 506  
TYPE: DNA  
ORGANISM: Homo sapiens  
FEATURE:  
OTHER INFORMATION: MAP TO AF134726.1  
OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 5.5  
OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 4.8  
OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 3.1  
OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 11  
OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 7.9  
OTHER INFORMATION: SWISSPROT HIT: P08107, EVALUE 2.00e-17  
OTHER INFORMATION: NT HIT: M59850.1, EVALUE 0.00e+00  
OTHER INFORMATION: EST\_HUMAN HIT: BG773197.1, EVALUE 0.00e+00  
US-10-029-386-6557

Query Match 76.1%; Score 163.6; DB 16; Length 506;  
Best Local Similarity 88.1%; Pred. No. 7.9e-44;  
Matches 178; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

OY 1 ATAAAGGCTAGGCTGAGAGCTGCTGCGACAGTCCACTACTCTTTTCGAGAGTGAATCC 60  
DB 339 AAAAGGCGGAGGCTTGAAGAGCTGCTGCGAGGCTCCGCTTCTTTCAGAGTGAATCC 280  
OY 61 GTTGTCCAGAGGCTTCCAGAGCGAAGCTGTGCGGCTGCGAGCACCGGCGCTGAGTTT 120  
DB 279 GCGGTCCAGAGGCTTTCAGAGCGAAGCTGTGCGGCTGCGAGCACCGGCGCTGAGTTT 220  
OY 121 CCGGCTCCGAGAGGAGCGAGTCTTTCGCGGATCCAGTGTTCGCTTTCAGAGCCCCCA 180  
DB 219 CCGGCTCCGAGAGGAGCGAGTCTTTCGCGGATCCAGTGTTCGCTTTCAGAGCCCCCA 160  
OY 181 TCTCAGAGCGGAGCGAGAG 202  
DB 159 TCTCAGAGCGGAGCGAGAG 138

RESULT 8  
US-10-425-115-89981  
Sequence 89981, Application US/10425115  
Publication No. US20040214272A1  
GENERAL INFORMATION:  
APPLICANT: La Rosa, Thomas J.  
APPLICANT: Kovalic, David K.

APPLICANT: Zhou, Yihua  
APPLICANT: Cao, Yongwei  
TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated with  
TITLE OF INVENTION: Plants  
FILE REFERENCE: 38-21(53222)B  
CURRENT APPLICATION NUMBER: US/10/425,115  
CURRENT FILING DATE: 2003-04-28  
NUMBER OF SEQ ID NOS: 369326  
SEQ ID NO: 89981  
LENGTH: 284  
TYPE: DNA  
ORGANISM: Zea mays  
FEATURE:  
OTHER INFORMATION: Clone ID: MRT4577\_182065C.1  
US-10-425-115-89981

Query Match 73.6%; Score 158.2; DB 18; Length 284;  
Best Local Similarity 95.3%; Pred. No. 4,5e-42;  
Matches 163; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 45 TTCGAGAGTACTCCCGTTGTCACAAAGCTTCCAGAGGAACTGTGGGCTGAGAGCA 104  
Db 1 TTCGAGAGTACTCCCGTTGTCACAAAGCTTCCAGAGGAACTGTGGGCTGAGAGCA 60  
Qy 105 CCGGCGCGTCCGAGTTTCCGCGCTCCGGAAGAACCGACTTCTGCGGATCCAGTTC 164  
Db 61 CCGGCGCGTCCGAGTTTCCGCGCTCCGGAAGAACCGACTTCTGCGGATCCAGTTC 120  
Qy 165 CGTTCCAGACCCCAATCTCAGAGCCGAGCCAGAGAGAGGAGGAGCCG 215  
Db 121 CGTTCCAGACCCCAATCTCAGAGCCGAGCCAGAGAGTGCAGATCCGCG 171

RESULT 9  
US-09-919-039-145  
Sequence 145, Application US/09919039  
Publication No. US20030108871A1  
GENERAL INFORMATION:  
APPLICANT: Kasef, Matthew R.  
TITLE OF INVENTION: GENES EXPRESSED IN TREATED HUMAN C3A LIVER CELL CULTURES  
FILE REFERENCE: PA-0035 US  
CURRENT APPLICATION NUMBER: US-09/919,039  
CURRENT FILING DATE: 2002-09-09  
PRIOR APPLICATION NUMBER: 60/222,113  
PRIOR FILING DATE: 2000-07-28  
NUMBER OF SEQ ID NOS: 401  
SOFTWARE: PERL Program  
SEQ ID NO: 145  
LENGTH: 2458  
TYPE: DNA  
ORGANISM: Homo sapiens  
FEATURE:  
NAME/KEY: misc feature  
OTHER INFORMATION: Incyte ID No. US20030108871A1 1678695CB1  
US-09-919-039-145

Query Match 72.9%; Score 156.8; DB 10; Length 2458;  
Best Local Similarity 88.5%; Pred. No. 1,5e-41;  
Matches 170; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

Qy 11 GCCTAGAGAGTCTGCGACAGTCCACTCTTTTCCAGAGTGAATCCCGTTGCCAA 70  
Db 1 GCCTAGAGAGTCTGCGAGGATCCGCTTCTTTCGAGAGTGAATCCCGGTCCTCA 60  
Qy 71 GCGTTCCAGAGCGAACTGTGCGGCTGAGGACCGGCGCTGAGTTTCCGCGCTCG 130  
Db 61 GCGTTCCAGAGCGAACTGTGCGGCTGAGGACCGGCGCTGAGTTTCCGCGCTTC 120  
Qy 131 GAAGAGCCAGCTCTTCTGCGGAGTCCAGTGTTCCTTTCCAGCCCCCAATCTCAGAGCC 190  
Db 121 GAAGAGCCAGCTCTTCTGCGGAGTCCAGTGTTCCTTTCCAGCCCCCAATCTCAGAGCC 180  
Qy 191 GAGCCGACAGAG 202

Db 181 GAGCCGACAGAG 192

RESULT 10  
US-10-335-053-290  
Sequence 290, Application US/10335053  
Publication No. US20040241653A1  
GENERAL INFORMATION:  
APPLICANT: Quark Biotech, Inc.  
TITLE OF INVENTION: Methods for identifying marker genes for cancer  
FILE REFERENCE: 68733-A; 070/US1  
CURRENT APPLICATION NUMBER: US/10/335,053  
CURRENT FILING DATE: 2003-03-27  
PRIOR APPLICATION NUMBER: 60/345,317  
PRIOR FILING DATE: 2001-12-31  
NUMBER OF SEQ ID NOS: 319  
SOFTWARE: Patentin version 3.2  
SEQ ID NO: 290  
LENGTH: 2513  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-335-053-290

Query Match 72.9%; Score 156.8; DB 18; Length 2513;  
Best Local Similarity 88.5%; Pred. No. 1,5e-41;  
Matches 170; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

Qy 11 GCCTAGAGAGTCTGCGACAGTCCACTCTTTTCCAGAGTGAATCCCGTTGCCAA 70  
Db 1 GCCTAGAGAGTCTGCGAGGATCCGCTTCTTTCGAGAGTGAATCCCGGTCCTCA 60  
Qy 71 GCGTTCCAGAGCGAACTGTGCGGCTGAGGACCGGCGCTGAGTTTCCGCGCTCG 130  
Db 61 GCGTTCCAGAGCGAACTGTGCGGCTGAGGACCGGCGCTGAGTTTCCGCGCTTC 120  
Qy 131 GAAGAGCCAGCTCTTCTGCGGAGTCCAGTGTTCCTTTCCAGCCCCCAATCTCAGAGCC 190  
Db 121 GAAGAGCCAGCTCTTCTGCGGAGTCCGCTTCCAGCCCCCAATCTCAGAGCC 180  
Qy 191 GAGCCGACAGAG 202  
Db 181 GAGCCGACAGAG 192

RESULT 11  
US-10-027-632-111980/C  
Sequence 111980, Application US/10027632  
Publication No. US20020198371A1  
GENERAL INFORMATION:  
APPLICANT: Wang, David G.  
TITLE OF INVENTION: Identification and Mapping of Single Nucleotide  
Polymorphisms in the Human Genome  
FILE REFERENCE: 108827.129  
CURRENT APPLICATION NUMBER: US/10/027,632  
CURRENT FILING DATE: 2002-04-30  
PRIOR APPLICATION NUMBER: US 60/218,006  
PRIOR FILING DATE: 2000-07-12  
PRIOR APPLICATION NUMBER: US 60/198,676  
PRIOR FILING DATE: 2000-04-20  
PRIOR APPLICATION NUMBER: US 60/193,483  
PRIOR FILING DATE: 2000-03-29  
PRIOR APPLICATION NUMBER: US 60/185,218  
PRIOR FILING DATE: 2000-02-24  
PRIOR APPLICATION NUMBER: US 60/167,363  
PRIOR FILING DATE: 1999-11-23  
PRIOR APPLICATION NUMBER: US 60/156,358  
PRIOR FILING DATE: 1999-09-28  
PRIOR APPLICATION NUMBER: US 60/146,002  
PRIOR FILING DATE: 1999-08-09  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO: 111980

LENGTH: 2771  
TYPE: DNA  
ORGANISM: Human  
US-10-027-632-111980

Query Match 72.7%; Score 156.4; DB 13; Length 2771;  
Best Local Similarity 99.4%; Pred. No. 2.1e-41;  
Matches 157; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

1 ATACGGCTAGCCTGAGGAGCGCTGCGACAGTCACTTTTTCAGAGTGAATGCC 60  
160 ATACGGCTAGCCTGAGGAGCGCTGCGACAGTCACTTTTTCAGAGTGAATGCC 101  
61 GTTGTCCCAAGGCTTCCAGAGCGAAGCTGTGCGCTGAGGACCGGCGCTGAGTTT 120  
100 GTTGTCCCAAGGCTTCCAGAGCGAAGCTGTGCGCTGAGGACCGGCGCTGAGTTT 41  
121 CCGGCGTCCGAGAGACCGAGCTCTTTCGCGGATCCA 158  
40 CCGGCGTCCGAGAGACCGAGCTCTTTCGCGGATCCA 3

RESULT 12  
US-10-027-632-111980/c  
Sequence 111980, Application US/10027632  
Publication No. US20030204075A9

GENERAL INFORMATION:  
APPLICANT: Wang, David G.  
TITLE OF INVENTION: Identification and Mapping of Single Nucleotide  
FILE REFERENCE: 108827.129  
CURRENT FILING DATE: 2002-04-30  
PRIOR FILING DATE: 2000-07-12  
PRIOR FILING DATE: 2000-07-12  
PRIOR FILING DATE: 2000-04-20  
PRIOR FILING DATE: 2000-04-20  
PRIOR FILING DATE: 2000-03-29  
PRIOR FILING DATE: 2000-03-29  
PRIOR FILING DATE: 2000-02-24  
PRIOR FILING DATE: 1999-11-23  
PRIOR FILING DATE: 1999-11-23  
PRIOR FILING DATE: 1999-09-28  
PRIOR FILING DATE: 1999-08-09  
NUMBER OF SEQ ID NOS: 325720  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 111980  
LENGTH: 2771  
TYPE: DNA  
ORGANISM: Human  
US-10-027-632-111980

Query Match 72.7%; Score 156.4; DB 17; Length 2771;  
Best Local Similarity 99.4%; Pred. No. 2.1e-41;  
Matches 157; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

1 ATACGGCTAGCCTGAGGAGCGCTGCGACAGTCACTTTTTCAGAGTGAATGCC 60  
160 ATACGGCTAGCCTGAGGAGCGCTGCGACAGTCACTTTTTCAGAGTGAATGCC 101  
61 GTTGTCCCAAGGCTTCCAGAGCGAAGCTGTGCGCTGAGGACCGGCGCTGAGTTT 120  
100 GTTGTCCCAAGGCTTCCAGAGCGAAGCTGTGCGCTGAGGACCGGCGCTGAGTTT 41  
121 CCGGCGTCCGAGAGACCGAGCTCTTTCGCGGATCCA 158  
40 CCGGCGTCCGAGAGACCGAGCTCTTTCGCGGATCCA 3

RESULT 13

US-10-363-345A-17429/c  
Sequence 17429, Application US/10363345A  
Publication No. US20040234960A1

GENERAL INFORMATION:  
APPLICANT: Alexander Olek  
APPLICANT: Christian Piepenbrock  
APPLICANT: Kurt Berlin  
TITLE OF INVENTION: Method for determining the degree of methylation of defined  
FILE REFERENCE: E01/1227  
CURRENT FILING DATE: 2003-03-03  
NUMBER OF SEQ ID NOS: 40712  
SEQ ID NO 17429  
LENGTH: 595  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: chemically treated genomic DNA (Homo sapiens)  
US-10-363-345A-17429

Query Match 67.5%; Score 145.2; DB 18; Length 595;  
Best Local Similarity 79.9%; Pred. No. 8.9e-38;  
Matches 171; Conservative 0; Mismatches 43; Indels 0; Gaps 0;

1 ATACGGCTAGCCTGAGGAGCGCTGCGACAGTCACTTTTTCAGAGTGAATGCC 60  
454 ATACGGCTAGCCTGAGGAGCGCTGCGACAGTCACTTTTTCAGAGTGAATGCC 395  
61 GTTGTCCCAAGGCTTCCAGAGCGAAGCTGTGCGCTGAGGACCGGCGCTGAGTTT 120  
394 GTTATCCCAAACTTCCCAAAAGCACTATACGATCAAAACCGGCGCTGAGTTT 335  
121 CCGGCGTCCGAGAGACCGAGCTCTTTCGCGGATCCAAGTTCGTTTCCAGCCCA 180  
334 CCGAGCTCCGAGAGACCGAGCTCTTTCGCGGATCCAAGTTCGTTTCCAGCCCA 275  
181 TCTCAGAGCGAGCGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 214  
274 TCTCAGAGCGAGCGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 241

RESULT 14  
US-10-363-345A-17430  
Sequence 17430, Application US/10363345A  
Publication No. US20040234960A1

GENERAL INFORMATION:  
APPLICANT: Alexander Olek  
APPLICANT: Christian Piepenbrock  
APPLICANT: Kurt Berlin  
TITLE OF INVENTION: Method for determining the degree of methylation of defined  
FILE REFERENCE: E01/1227  
CURRENT FILING DATE: 2003-03-03  
NUMBER OF SEQ ID NOS: 40712  
SEQ ID NO 17430  
LENGTH: 595  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: chemically treated genomic DNA (Homo sapiens)  
US-10-363-345A-17430

Query Match 67.5%; Score 145.2; DB 18; Length 595;  
Best Local Similarity 79.9%; Pred. No. 8.9e-38;  
Matches 171; Conservative 0; Mismatches 43; Indels 0; Gaps 0;

1 ATACGGCTAGCCTGAGGAGCGCTGCGACAGTCACTTTTTCAGAGTGAATGCC 60  
142 ATACGGCTAGCCTGAGGAGCGCTGCGACAGTCACTTTTTCAGAGTGAATGCC 201



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 11, 2005, 07:40:18 ; Search time 1641 Seconds  
(without alignments)  
4987.092 Million cell updates/sec

Title: US-09-936-506-1

Perfect score: 215  
Sequence: 1 ataacgcctagcctcgtgagag.....gacagagcagcaggaaccgc 215

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 1.0

Searched: 34239544 seqs, 19032134700 residues

Total number of hits satisfying chosen parameters: 68479088

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : EST:  
1: gb\_est1:  
2: gb\_est2:  
3: gb\_hic:  
4: gb\_est3:  
5: gb\_est4:  
6: gb\_est5:  
7: gb\_est6:  
8: gb\_gsa1:  
9: gb\_gsa2:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	214	99.5	642	7	CN397686 170005326
2	214	99.5	2380	3	CR605652 full-length
3	214	99.5	2383	3	CR598680 full-length
4	214	99.5	2387	3	CR626292 full-length
5	214	99.5	2391	3	CR608110 full-length
6	214	99.5	2396	3	CR599258 full-length
7	214	99.5	2398	3	CR618761 full-length
8	214	99.5	2398	3	CR621778 full-length
9	214	99.5	2398	3	CR606872 full-length
10	214	99.5	2401	3	CR595673 full-length
11	214	99.5	2409	3	CR624878 full-length
12	214	99.5	2417	3	CR603812 full-length
13	212.4	98.8	356	6	CB112917 K-EST0154
14	212.4	98.8	493	6	BO639435 bel5e11.Y
15	212.4	98.8	511	6	CB154948 K-EST0213
16	212.4	98.8	527	6	CB141518 K-EST0195
17	212.4	98.8	590	6	CB138426 K-EST0191
18	212.4	98.8	701	4	BG773197 602721934
19	212.4	98.8	816	4	BG485554 602505445
20	212.4	98.8	912	4	B1462679 603202121
21	212	98.6	582	4	BP350439 BP350439
22	211.4	98.3	751	4	B1464037 603202811
23	211	98.1	570	5	BP259174 BP259174
24	210.8	98.0	582	5	BP245573 BP245573

25	210.8	98.0	584	5	BP232134 BP232134
26	210.4	97.9	267	1	AU076824 AU076824
27	210.4	97.9	316	4	BM622968 K-EST0093
28	210.4	97.9	376	6	CB133590 K-EST0184
29	210.4	97.9	409	6	CB133685 K-EST0184
30	210.4	97.9	436	4	B1548281 B1548281
31	210.4	97.9	463	6	CB137170 K-EST0189
32	210.4	97.9	479	6	CB133251 K-EST0184
33	210.4	97.9	505	6	CB133452 K-EST0184
34	210.4	97.9	509	6	CB134000 K-EST0185
35	210.4	97.9	509	6	CB138961 K-EST0191
36	210.4	97.9	516	6	CB137829 K-EST0190
37	210.4	97.9	516	6	CB138598 K-EST0191
38	210.4	97.9	522	6	CB133953 K-EST0185
39	210.4	97.9	523	6	CB152005 K-EST0209
40	210.4	97.9	523	6	CB152693 K-EST0209
41	210.4	97.9	526	5	BP382860 BP382860
42	210.4	97.9	532	6	CB153107 K-EST0210
43	210.4	97.9	533	6	CB133518 K-EST0184
44	210.4	97.9	546	6	CB155190 K-EST0213
45	210.4	97.9	581	5	BP231177 BP231177

## ALIGNMENTS

RESULT 1  
LOCUS CN397686 642 bp. mRNA linear EST 16-MAY-2004  
DEFINITION 17000532601385 GRN\_ES Homo sapiens cDNA 5', mRNA sequence.  
ACCESSION CN397686  
VERSION CN397686.1 GI:47385281  
KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1 (bases 1 to 642)  
Brandenberger, R., Wei, H., Zhang, S., Lei, S., Murage, J., Fisk, G.J.,  
Li, Y., Xu, C., Fang, R., Guegler, K., Rao, M.S., Mandalam, R.,  
Lebkowski, J., and Stanton, L.W.

Transcriptome characterization elucidates signaling networks that  
control human ES cell growth and differentiation  
Nat. Biotechnol. 22 (6), 707-716 (2004)

JOURNAL Contact: Brandenberger R

COMMENT

Regenerative Medicine  
Geron Corporation  
230 Constitution Drive, Menlo Park, CA 94025, USA  
Tel: 650 473 8658  
Fax: 650 473 7760  
Email: rbrandenberger@geron.com  
Insert Length: 642 Std Error: 0.00.  
Location/Qualifiers

FEATURES  
source

1..642  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/tissue\_type="Embryonic stem cells, cell lines H1, H7, and H9"  
/clone\_lib="GRN ES"  
/note="Oligo dt primed, full-length enriched cDNA library from undifferentiated hES cell lines H1 (p32), H7 (p29), and H9 (p26) maintained in feeder-free conditions"

ORIGIN

Query Match 99.5%; Score 214; DB 7; Length 642;

Best Local Similarity 100.0%; Pred. No. 6,6e-51;  
Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CY 1 ATTAAGGCTAGAGCTGCTGCGACAGTCCACATCACTTTTCGAGATGATCC 60  
DB 78 ATTAAGGCTAGAGCTGCTGCGACAGTCCACATCACTTTTCGAGATGATCC 137

QY 61 GTTGTCCCAAGGCTTCCCAAGCGAACCCTGTGCGGTGAGGACCGGCGCTCGAGTTT 120  
Db 138 GTTGTCCCAAGGCTTCCCAAGCGAACCCTGTGCGGTGAGGACCGGCGCTCGAGTTT 197  
QY 121 CCGGCGTCCGAAGACCGAGCTCTTCTCGCGATCAGTGTTCGTTTCCAGCCCCCA 180  
Db 198 CCGGCGTCCGAAGACCGAGCTCTTCTCGCGATCAGTGTTCGTTTCCAGCCCCCA 257  
QY 181 TCTCAGAGCCGACCGACAGAGAGGAGGACCG 214  
Db 258 TCTCAGAGCCGACCGACAGAGAGGAGGACCG 291

RESULT 2  
CR605652 2380 bp mRNA linear HTC 21-JUL-2004  
LOCUS Full-length cDNA clone CS0DF033YK03 of Fetal brain of Homo sapiens (human).  
ACCESSION CR605652.1 GI:50486459  
VERSION CR605652.1  
KEYWORDS HTC; CNSLT\_cDNA.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.  
REFERENCE 1 (bases 1 to 2380)  
AUTHORS Li, W.B., Gruber, C., Jessee, J. and Polayes, D.  
TITLE Full-length cDNA libraries and normalization  
JOURNAL Unpublished  
CONTACT : Feng Liang Email : fliang@lifetech.com URL : http://fulllength.invitrogen.com/ Invitrogen Corporation 1600 Faraday Avenue  
REMARK 2 (bases 1 to 2380)  
REFERENCE 2  
AUTHORS Genoscope.  
TITLE Direct Submission  
JOURNAL Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage : BP 191 91006 EVRY cedex - FRANCE (E-mail : secrete@genoscope.cns.fr  
- Web : www.genoscope.cns.fr)  
1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized. Library was constructed by Life Technologies, a division of Invitrogen.  
FEATURES  
source  
Location/Qualifiers  
1..2380  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="CS0DF033YK03"  
/tissue\_type="Fetal brain"  
/plasmid="pCMVSPORT\_6"

ORIGIN  
Query Match 99.5%; Score 214; DB 3; Length 2380;  
Best Local Similarity 100.0%; Pred. No. 7.9e-51;  
Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATAAAGGCTAGGCTAGAGGAGTCTGCGACAGTCCACTCTTTTCGAGAGTGAATCCC 60  
Db 14 ATAAAGGCTAGGCTAGAGGAGTCTGCGACAGTCCACTCTTTTCGAGAGTGAATCCC 73  
QY 61 GTTGTCCCAAGGCTTCCCAAGCGAACCCTGTGCGGTGAGGACCGGCGCTCGAGTTT 120  
Db 74 GTTGTCCCAAGGCTTCCCAAGCGAACCCTGTGCGGTGAGGACCGGCGCTCGAGTTT 133  
QY 121 CCGGCGTCCGAAGACCGAGCTCTTCTCGCGATCAGTGTTCGTTTCCAGCCCCCA 180  
Db 134 CCGGCGTCCGAAGACCGAGCTCTTCTCGCGATCAGTGTTCGTTTCCAGCCCCCA 193  
QY 181 TCTCAGAGCCGACCGACAGAGAGGAGGACCG 214  
Db 194 TCTCAGAGCCGACCGACAGAGAGGAGGACCG 227

RESULT 3  
CR598680 2383 bp mRNA linear HTC 21-JUL-2004  
LOCUS Full-length cDNA clone CS0DC028YK15 of Neuroblastoma Cot 25-normalized of Homo sapiens (human).  
ACCESSION CR598680.1 GI:50479487  
VERSION CR598680.1  
KEYWORDS HTC; CNSLT\_cDNA.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.  
REFERENCE 1 (bases 1 to 2383)  
AUTHORS Li, W.B., Gruber, C., Jessee, J. and Polayes, D.  
TITLE Full-length cDNA libraries and normalization  
JOURNAL Unpublished  
CONTACT : Feng Liang Email : fliang@lifetech.com URL : http://fulllength.invitrogen.com/ Invitrogen Corporation 1600 Faraday Avenue  
REMARK 2 (bases 1 to 2383)  
REFERENCE 2  
AUTHORS Genoscope.  
TITLE Direct Submission  
JOURNAL Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage : BP 191 91006 EVRY cedex - FRANCE (E-mail : secrete@genoscope.cns.fr  
- Web : www.genoscope.cns.fr)  
1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized. Library was constructed by Life Technologies, a division of Invitrogen.  
FEATURES  
source  
Location/Qualifiers  
1..2383  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="CS0DC028YK15"  
/tissue\_type="Neuroblastoma Cot 25-normalized"  
/plasmid="pCMVSPORT\_6"

ORIGIN  
Query Match 99.5%; Score 214; DB 3; Length 2383;  
Best Local Similarity 100.0%; Pred. No. 7.9e-51;  
Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATAAAGGCTAGGCTAGAGGAGTCTGCGACAGTCCACTCTTTTCGAGAGTGAATCCC 60  
Db 14 ATAAAGGCTAGGCTAGAGGAGTCTGCGACAGTCCACTCTTTTCGAGAGTGAATCCC 73  
QY 61 GTTGTCCCAAGGCTTCCCAAGCGAACCCTGTGCGGTGAGGACCGGCGCTCGAGTTT 120  
Db 74 GTTGTCCCAAGGCTTCCCAAGCGAACCCTGTGCGGTGAGGACCGGCGCTCGAGTTT 133  
QY 121 CCGGCGTCCGAAGACCGAGCTCTTCTCGCGATCAGTGTTCGTTTCCAGCCCCCA 180  
Db 134 CCGGCGTCCGAAGACCGAGCTCTTCTCGCGATCAGTGTTCGTTTCCAGCCCCCA 193  
QY 181 TCTCAGAGCCGACCGACAGAGAGGAGGACCG 214  
Db 194 TCTCAGAGCCGACCGACAGAGAGGAGGACCG 227

RESULT 4  
CR626292 2387 bp mRNA linear HTC 21-JUL-2004  
LOCUS Full-length cDNA clone CS0DF038YK05 of Fetal brain of Homo sapiens (human).  
ACCESSION CR626292.1 GI:50507099  
VERSION CR626292.1  
KEYWORDS HTC; CNSLT\_cDNA.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;



REFERENCE Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
1 (bases 1 to 2387)  
AUTHORS Li, W.B., Gruber, C., Jessee, J. and Polayes, D.  
TITLE Full-length cDNA libraries and normalization  
JOURNAL Unpublished  
REMARK Contact: Feng Liang Email: fliang@lifeitech.com URL:  
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600  
Paraday Avenue  
Genoscope.  
2 (bases 1 to 2387)  
REFERENCE  
AUTHORS Direct Submission  
TITLE Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage :  
JOURNAL BP 191 91006 EVRY cedex - FRANCE (E-mail : sequef@genoscope.cns.fr  
- Web : www.genoscope.cns.fr)  
COMMENT 1st strand cDNA was primed with a NotI-oligo(dt) primer. Five prime  
end enriched, double-strand cDNA was digested with Not I and cloned  
into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library  
was normalized. Library was constructed by Life Technologies, a  
division of Invitrogen.  
FEATURES  
source  
1..2387  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="CSODF038YK05"  
/tissue\_type="Fetal brain"  
/plasmid="pCMVSPORT\_6"  
ORIGIN  
Query Match 99.5%; Score 214; DB 3; Length 2387;  
Best Local Similarity 100.0%; Pred. No. 7.9e-51;  
Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 ATACGGCTAGCTTCCAGAGCTGCTCCGACAGTCCACTTCTTTCCAGAGTACTCCC 60  
DB 14 ATAAAGGCTAGCTTCCAGAGCTGCTCCGACAGTCCACTTCTTTCCAGAGTACTCCC 73  
QY 61 GTTGTCCCAAGGCTTCCAGAGCTGCTCCGAGCTGAGGACCGGCGCTCGAGTTT 120  
DB 74 GTTGTCCCAAGGCTTCCAGAGCTGCTCCGAGCTGAGGACCGGCGCTCGAGTTT 133  
QY 121 CCGGCTCCGAGAGGACCGAGCTCTTCTCGCGAGTCCAGTGTTCGTTTCCAGCCCCA 180  
DB 134 CCGGCTCCGAGAGGACCGAGCTCTTCTCGCGAGTCCAGTGTTCGTTTCCAGCCCCA 193  
QY 181 TCTCAGAGCCGAGCCGAGAGAGAGAGAGGAGGACCG 214  
DB 194 TCTCAGAGCCGAGCCGAGAGAGAGAGAGGAGGACCG 227  
RESULT 5  
CR608110 2391 bp mRNA linear HTC 21-JUL-2004  
LOCUS full-length cDNA clone CS0DJ004YG01 of T cells (Jurkat cell line)  
DEFINITION Cot 10-normalized of Homo sapiens (human).  
ACCESSION CR608110  
VERSION CR608110.1 GI:50488917  
KEYWORDS HTC; CNSLT\_cDNA.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
1 (bases 1 to 2391)  
AUTHORS Li, W.B., Gruber, C., Jessee, J. and Polayes, D.  
TITLE Full-length cDNA libraries and normalization  
JOURNAL Unpublished  
REMARK Contact: Feng Liang Email: fliang@lifeitech.com URL:  
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600  
Paraday Avenue  
Genoscope.  
2 (bases 1 to 2391)  
REFERENCE  
AUTHORS Direct Submission  
TITLE Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage :  
JOURNAL

COMMENT BP 191 91006 EVRY cedex - FRANCE (E-mail : sequef@genoscope.cns.fr  
- Web : www.genoscope.cns.fr)  
1st strand cDNA was primed with a NotI-oligo(dt) primer. Five prime  
end enriched, double-strand cDNA was digested with Not I and cloned  
into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library  
was normalized. Library was constructed by Life Technologies, a  
division of Invitrogen.  
FEATURES  
source  
1..2391  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="CSODJ004YG01"  
/tissue\_type="T cells (Jurkat cell line) Cot  
10-normalized"  
/plasmid="pCMVSPORT\_6"  
ORIGIN  
Query Match 99.5%; Score 214; DB 3; Length 2391;  
Best Local Similarity 100.0%; Pred. No. 7.9e-51;  
Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 ATACGGCTAGCTTCCAGAGCTGCTCCGACAGTCCACTTCTTTCCAGAGTACTCCC 60  
DB 29 ATAAAGGCTAGCTTCCAGAGCTGCTCCGACAGTCCACTTCTTTCCAGAGTACTCCC 88  
QY 61 GTTGTCCCAAGGCTTCCAGAGCTGCTCCGAGCTGAGGACCGGCGCTCGAGTTT 120  
DB 89 GTTGTCCCAAGGCTTCCAGAGCTGCTCCGAGCTGAGGACCGGCGCTCGAGTTT 148  
QY 121 CCGGCTCCGAGAGGACCGAGCTCTTCTCGCGAGTCCAGTGTTCGTTTCCAGCCCCA 180  
DB 149 CCGGCTCCGAGAGGACCGAGCTCTTCTCGCGAGTCCAGTGTTCGTTTCCAGCCCCA 208  
QY 181 TCTCAGAGCCGAGCCGAGAGAGAGAGGAGGAGGACCG 214  
DB 209 TCTCAGAGCCGAGCCGAGAGAGAGAGGAGGAGGACCG 242  
RESULT 6  
CR599258 2396 bp mRNA linear HTC 21-JUL-2004  
LOCUS full-length cDNA clone CS0DF007YE19 of Fetal brain of Homo sapiens  
DEFINITION (human).  
ACCESSION CR599258  
VERSION CR599258.1 GI:50480065  
KEYWORDS HTC; CNSLT\_cDNA.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
1 (bases 1 to 2396)  
AUTHORS Li, W.B., Gruber, C., Jessee, J. and Polayes, D.  
TITLE Full-length cDNA libraries and normalization  
JOURNAL Unpublished  
REMARK Contact: Feng Liang Email: fliang@lifeitech.com URL:  
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600  
Paraday Avenue  
Genoscope.  
2 (bases 1 to 2396)  
REFERENCE  
AUTHORS Direct Submission  
TITLE Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage :  
JOURNAL BP 191 91006 EVRY cedex - FRANCE (E-mail : sequef@genoscope.cns.fr  
- Web : www.genoscope.cns.fr)  
COMMENT 1st strand cDNA was primed with a NotI-oligo(dt) primer. Five prime  
end enriched, double-strand cDNA was digested with Not I and cloned  
into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library  
was normalized. Library was constructed by Life Technologies, a  
division of Invitrogen.  
FEATURES  
source  
1..2396  
/organism="Homo sapiens"  
/mol\_type="mRNA"

## ORIGIN

/db\_xref="taxon:9606"  
/clone="CS0DF0071E19"  
/tissue="Fetal Brain"  
/plasmid="pCMVSPORT\_6"

## Query Match

Best Local Similarity 99.5%; Score 214; DB 3; Length 2396;  
Matches 214; Conservativity 100.0%; Pred. No. 7.9e-51; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATAAAGGCTAGCCTGAGAGAGCTGCTGCGACAGTCCACTCTTTTTCAGAGTGAATCCC 60  
DB 14 ATAAAGGCTAGCCTGAGAGAGCTGCTGCGACAGTCCACTCTTTTTCAGAGTGAATCCC 73  
QY 61 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGAGGACCGGCGCTGAGATT 120  
DB 74 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGAGGACCGGCGCTGAGATT 133  
QY 121 CCGGGGTCCGGAAGAACCGAGCTCTTCTGCGGATTCAGTGTTCGTTCCAGCCCCCA 180  
DB 134 CCGGGGTCCGGAAGAACCGAGCTCTTCTGCGGATTCAGTGTTCGTTCCAGCCCCCA 193  
QY 181 TCTCAGAGCCGAGCCGACAGAGAGGAAACCG 214  
DB 194 TCTCAGAGCCGAGCCGACAGAGAGGAAACCG 227

## RESULT 7

CR618761

LOCUS full-length cDNA clone CS0DN003YF07 of Adult brain of Homo sapiens (human). 2398 bp mRNA linear HTC 21-JUL-2004

## ACCESSION

CR618761

VERSION CR618761.1 GI:50499568

## KEYWORDS

HTC; CNSLT CDNA.

## SOURCE

Homo sapiens (human)

## ORGANISM

Homo sapiens

## REFERENCE

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

## AUTHORS

Li, W.B., Gruber, C., Jessee, J., and Polayes, D.

## TITLE

Full-length cDNA libraries and normalization

## JOURNAL

Unpublished

## REMARK

Contact : Feng Liang Email : fliang@lifetech.com URL : http://fulllength.invitrogen.com/ Invitrogen Corporation 1600 Faraday Avenue 2 (bases 1 to 2398)

## REFERENCE

Genoscope.

## AUTHORS

Direct Submission

## TITLE

Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage : BP 191 91006 EVRY cedex - FRANCE (E-mail : sequef@genoscope.cns.fr)

## JOURNAL

- Web : www.genoscope.cns.fr

## COMMENT

1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized. Library was constructed by Life Technologies, a division of Invitrogen.

## FEATURES

Location/Qualifiers

1..2398

/organism="Homo sapiens"

/mol\_type="mRNA"

/db\_xref="taxon:9606"

/clone="CS0DN003YF07"

/tissue="Adult brain"

/plasmid="pCMVSPORT\_6"

## ORIGIN

## Query Match

Best Local Similarity 99.5%; Score 214; DB 3; Length 2396;  
Matches 214; Conservativity 100.0%; Pred. No. 7.9e-51; Mismatches 0; Indels 0; Gaps 0;

1 ATAAAGGCTAGCCTGAGAGAGCTGCTGCGACAGTCCACTCTTTTTCAGAGTGAATCCC 60  
|||||

## DB

29 ATAAAGGCTAGCCTGAGAGAGCTGCTGCGACAGTCCACTCTTTTTCAGAGTGAATCCC 88

## QY

61 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGAGGACCGGCGCTGAGATT 120

## DB

89 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGAGGACCGGCGCTGAGATT 148

## QY

121 CCGGGGTCCGGAAGAACCGAGCTCTTCTGCGGATTCAGTGTTCGTTCCAGCCCCCA 180

## DB

149 CCGGGGTCCGGAAGAACCGAGCTCTTCTGCGGATTCAGTGTTCGTTCCAGCCCCCA 208

## QY

181 TCTCAGAGCCGAGCCGACAGAGAGGAAACCG 214

## DB

209 TCTCAGAGCCGAGCCGACAGAGAGGAAACCG 242

## RESULT 8

CR621778

LOCUS full-length cDNA clone CS0DE003YF16 of Placenta of Homo sapiens (human). 2398 bp mRNA linear HTC 21-JUL-2004

## ACCESSION

CR621778

VERSION CR621778.1 GI:50502585

## KEYWORDS

HTC; CNSLT CDNA.

## SOURCE

Homo sapiens (human)

## ORGANISM

Homo sapiens

## REFERENCE

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

## AUTHORS

Li, W.B., Gruber, C., Jessee, J., and Polayes, D.

## TITLE

Full-length cDNA libraries and normalization

## JOURNAL

Unpublished

## REMARK

Contact : Feng Liang Email : fliang@lifetech.com URL : http://fulllength.invitrogen.com/ Invitrogen Corporation 1600 Faraday Avenue 2 (bases 1 to 2398)

## REFERENCE

Genoscope.

## AUTHORS

Direct Submission

## TITLE

Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage : BP 191 91006 EVRY cedex - FRANCE (E-mail : sequef@genoscope.cns.fr)

## JOURNAL

- Web : www.genoscope.cns.fr

## COMMENT

1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized. Library was constructed by Life Technologies, a division of Invitrogen.

## FEATURES

Location/Qualifiers

1..2398

/organism="Homo sapiens"

/mol\_type="mRNA"

/db\_xref="taxon:9606"

/clone="CS0DE003YF16"

/tissue="Placenta"

/plasmid="pCMVSPORT\_6"

## ORIGIN

## Query Match

Best Local Similarity 99.5%; Score 214; DB 3; Length 2396;  
Matches 214; Conservativity 100.0%; Pred. No. 7.9e-51; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATAAAGGCTAGCCTGAGAGAGCTGCTGCGACAGTCCACTCTTTTTCAGAGTGAATCCC 60  
DB 14 ATAAAGGCTAGCCTGAGAGAGCTGCTGCGACAGTCCACTCTTTTTCAGAGTGAATCCC 73  
QY 61 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGAGGACCGGCGCTGAGATT 120  
DB 74 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGAGGACCGGCGCTGAGATT 133  
QY 121 CCGGGGTCCGGAAGAACCGAGCTCTTCTGCGGATTCAGTGTTCGTTCCAGCCCCCA 180  
DB 134 CCGGGGTCCGGAAGAACCGAGCTCTTCTGCGGATTCAGTGTTCGTTCCAGCCCCCA 193  
QY 181 TCTCAGAGCCGAGCCGACAGAGAGGAAACCG 214  
|||||

Db 194 TCTCAGAGCCGAGCCGAGAGAGAGGAAACCG 227

RESULT 9  
LOCUS CR606872 2399 bp mRNA linear HTC 21-JUL-2004  
DEFINITION full-length cDNA clone CS0DF021Y109 of Fetal Brain of Homo sapiens (human).

ACCESSION CR606872.1 GI:50487679  
VERSION CR606872.1  
KEYWORDS HTC; CNSLT; cDNA.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens

REFERENCE  
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
TITLE Li, W.B., Gruber, C., Jessee, J. and Polayes, D.  
JOURNAL Full-length cDNA libraries and normalization  
REMARK Unpublished  
Contact: Feng Liang Email: fliang@lifetech.com URL: http://fulllength.invitrogen.com/InvitrogenCorporation1600  
Faraday Avenue 1600

REFERENCE  
AUTHORS 2 (bases 1 to 2399)  
TITLE Genoscope.  
JOURNAL Direct Submission  
Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage : BP 191 91006 EVRY cedex - FRANCE (E-mail: sequef@genoscope.cns.fr - Web : www.genoscope.cns.fr)  
1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized. Library was constructed by Life Technologies, a division of Invitrogen.

FEATURES  
source Location/Qualifiers  
1..2399  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="CS0DF021Y109"  
/tissue\_type="Fetal brain"  
/plasmid="pCMVSPORT\_6"

COMMENT  
Query Match 99.5%; Score 214; DB 3; Length 2399;  
Best Local Similarity 100.0%; Pred. No. 7.9e-51;  
Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

ORIGIN  
1 ATACGGCTAGCCTGAGAGCTGTGCGACAGTCCACTTCTTTTCGAGAGTGAATCCC  
2 14 ATACGGCTAGCCTGAGAGCTGTGCGACAGTCCACTTCTTTTCGAGAGTGAATCCC  
3 61 GTTGTCCTCAGAGCTTCCAGAGCGAACTGTGCGGCTGAGGACCGCGCGCTGAGATT  
4 74 GTTGTCCTCAGAGCTTCCAGAGCGAACTGTGCGGCTGAGGACCGCGCGCTGAGATT  
5 121 CCGGGCTCCGAGAGACCGAGCTCTTCTGCGGATCCAGTGTTCGTTTCCAGCCCA  
6 134 CCGGGCTCCGAGAGACCGAGCTCTTCTGCGGATCCAGTGTTCGTTTCCAGCCCA  
7 181 TCTCAGAGCCGAGCCGAGAGAGAGGAAACCG 214  
8 194 TCTCAGAGCCGAGCCGAGAGAGAGGAAACCG 227

RESULT 10  
LOCUS CR595673 2401 bp mRNA linear HTC 21-JUL-2004  
DEFINITION full-length cDNA clone CS0DB002YK13 of Placenta of Homo sapiens (human).

ACCESSION CR595673.1 GI:50476480  
VERSION CR595673.1  
KEYWORDS HTC; CNSLT; cDNA.  
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
TITLE Li, W.B., Gruber, C., Jessee, J. and Polayes, D.  
JOURNAL Full-length cDNA libraries and normalization  
REMARK Unpublished  
Contact: Feng Liang Email: fliang@lifetech.com URL: http://fulllength.invitrogen.com/InvitrogenCorporation1600  
Faraday Avenue 1600

REFERENCE  
AUTHORS 2 (bases 1 to 2401)  
TITLE Genoscope.  
JOURNAL Direct Submission  
Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage : BP 191 91006 EVRY cedex - FRANCE (E-mail: sequef@genoscope.cns.fr - Web : www.genoscope.cns.fr)  
1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized. Library was constructed by Life Technologies, a division of Invitrogen.

FEATURES  
source Location/Qualifiers  
1..2401  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="CS0DB002YK13"  
/tissue\_type="Placenta"  
/plasmid="pCMVSPORT\_6"

COMMENT  
Query Match 99.5%; Score 214; DB 3; Length 2401;  
Best Local Similarity 100.0%; Pred. No. 7.9e-51;  
Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

ORIGIN  
1 ATACGGCTAGCCTGAGAGCTGTGCGACAGTCCACTTCTTTTCGAGAGTGAATCCC  
2 29 ATACGGCTAGCCTGAGAGCTGTGCGACAGTCCACTTCTTTTCGAGAGTGAATCCC  
3 61 GTTGTCCTCAGAGCTTCCAGAGCGAACTGTGCGGCTGAGGACCGCGCGCTGAGATT  
4 89 GTTGTCCTCAGAGCTTCCAGAGCGAACTGTGCGGCTGAGGACCGCGCGCTGAGATT  
5 121 CCGGGCTCCGAGAGACCGAGCTCTTCTGCGGATCCAGTGTTCGTTTCCAGCCCA  
6 149 CCGGGCTCCGAGAGACCGAGCTCTTCTGCGGATCCAGTGTTCGTTTCCAGCCCA  
7 181 TCTCAGAGCCGAGCCGAGAGAGAGGAAACCG 214  
8 209 TCTCAGAGCCGAGCCGAGAGAGAGGAAACCG 242

RESULT 11  
LOCUS CR624878 2409 bp mRNA linear HTC 21-JUL-2004  
DEFINITION full-length cDNA clone CS0DF012YK23 of Fetal Brain of Homo sapiens (human).

ACCESSION CR624878.1 GI:50505685  
VERSION CR624878.1  
KEYWORDS HTC; CNSLT; cDNA.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens

REFERENCE  
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
TITLE Li, W.B., Gruber, C., Jessee, J. and Polayes, D.  
JOURNAL Full-length cDNA libraries and normalization  
REMARK Unpublished  
Contact: Feng Liang Email: fliang@lifetech.com URL: http://fulllength.invitrogen.com/InvitrogenCorporation1600  
Faraday Avenue 1600

REFERENCE  
AUTHORS 2 (bases 1 to 2409)  
TITLE Genoscope.

TITLE Direct Submission  
JOURNAL Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage :  
BP 191 91006 EVRY cedex - FRANCE (E-mail : sequef@genoscope.cns.fr  
- Web : www.genoscope.cns.fr)  
COMMENT 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime  
end enriched, double-strand cDNA was digested with Not I and cloned  
into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library  
was normalized. Library was constructed by Life Technologies, a  
division of Invitrogen.  
FEATURES  
source Location/Qualifiers  
1..2409  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="CS0DF012YA23"  
/tissue\_type="Fetal brain"  
/plasmid="pCMVSPORT\_6"

ORIGIN  
Query Match 99.5%; Score 214; DB 3; Length 2409;  
Best Local Similarity 100.0%; Pred. No. 7.9e-51;  
Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATTAAGGCTACGCTTCCAGAGAGCTGCTGCGACAGTCCACTTCTTTCCAGAGTACTCC 60  
DB 14 ATTAAGGCTACGCTTCCAGAGAGCTGCTGCGACAGTCCACTTCTTTCCAGAGTACTCC 73  
QY 61 GTTGTCCCAAGGCTTCCAGAGAGCACTGTGCGGCTGACGACACCGGCGCTGAGTTT 120  
DB 74 GTTGTCCCAAGGCTTCCAGAGAGCACTGTGCGGCTGACGACACCGGCGCTGAGTTT 133  
QY 121 CCGGCGTCCGGAAGAGACCGAGCTCTTCTGCGGATCCAGTGTTCGTTCCAGCCCCCA 180  
DB 134 CCGGCGTCCGGAAGAGACCGAGCTCTTCTGCGGATCCAGTGTTCGTTCCAGCCCCCA 193  
QY 181 TCTCAGAGCCGAGCGAGACAGAGAGGAGACCG 214  
DB 194 TCTCAGAGCCGAGCGAGACAGAGAGGAGACCG 227

RESULT 12  
LOCUS CR603812 2417 bp mRNA linear HTC 21-JUL-2004  
DEFINITION Full-length cDNA clone CS0DF020YJ02 of fetal brain of Homo sapiens  
(human).  
ACCESSION CR603812  
VERSION CR603812.1 GI:50484619  
KEYWORDS HTC; cNSLT\_cDNA.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.  
REFERENCE 1 (bases 1 to 2417)  
AUTHORS Li, W.B., Gruber, C., Jessee, J. and Polayes, D.  
JOURNAL Full-length cDNA libraries and normalization  
TITLE Unpublished  
CONTACT : Feng Liang Email : fliang@life.techn.com URL :  
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600  
REMARK Faraday Avenue  
2 (bases 1 to 2417)  
Genoscope.  
REFERENCE Direct Submission  
AUTHORS Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage :  
BP 191 91006 EVRY cedex - FRANCE (E-mail : sequef@genoscope.cns.fr  
- Web : www.genoscope.cns.fr)  
COMMENT 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime  
end enriched, double-strand cDNA was digested with Not I and cloned  
into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library  
was normalized. Library was constructed by Life Technologies, a  
division of Invitrogen.  
FEATURES  
source Location/Qualifiers  
1..2417  
/organism="Homo sapiens"

ORIGIN  
Query Match 99.5%; Score 214; DB 3; Length 2417;  
Best Local Similarity 100.0%; Pred. No. 7.9e-51;  
Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATTAAGGCTACGCTTCCAGAGAGCTGCTGCGACAGTCCACTTCTTTCCAGAGTACTCC 60  
DB 29 ATTAAGGCTACGCTTCCAGAGAGCTGCTGCGACAGTCCACTTCTTTCCAGAGTACTCC 88  
QY 61 GTTGTCCCAAGGCTTCCAGAGAGCACTGTGCGGCTGACGACACCGGCGCTGAGTTT 120  
DB 89 GTTGTCCCAAGGCTTCCAGAGAGCACTGTGCGGCTGACGACACCGGCGCTGAGTTT 148  
QY 121 CCGGCGTCCGGAAGAGACCGAGCTCTTCTGCGGATCCAGTGTTCGTTCCAGCCCCCA 180  
DB 149 CCGGCGTCCGGAAGAGACCGAGCTCTTCTGCGGATCCAGTGTTCGTTCCAGCCCCCA 208  
QY 181 TCTCAGAGCCGAGCGAGACAGAGAGGAGACCG 214  
DB 209 TCTCAGAGCCGAGCGAGACAGAGAGGAGACCG 242

RESULT 13  
LOCUS CB112917 356 bp mRNA linear EST 28-JAN-2003  
DEFINITION K-BST0154803 L6Chock0 Homo sapiens cDNA clone L6Chock0-10-A11 5',  
mRNA sequence.  
ACCESSION CB112917  
VERSION CB112917.1 GI:27938724  
KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.  
REFERENCE 1 (bases 1 to 356)  
AUTHORS Kim, N.S., Hahn, Y., Oh, J.H., Lee, J.Y., Ahn, H.Y., Chu, M.Y., Kim, M.R.,  
Oh, K.U., Cheong, J.E., Sohn, H.Y., Kim, J.W., Park, H.S., Kim, S. and  
Kim, Y.S.  
JOURNAL 21C Frontiers Korean EST Project 2001  
COMMENT Unpublished (2002)  
Contact: Kim YS  
Genome Research Center  
Korea Research Institute of Bioscience & Biotechnology  
52 Boeun-dong Yuseong-gu, Daejeon 305-333, South Korea  
Tel: +82-42-860-4470  
Fax: +82-42-860-4409  
Email: yongsung@mail.kribb.re.kr  
Plate: 10 row: A column: 11  
High quality sequence stop: 356.  
FEATURES  
source Location/Qualifiers  
1..356  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="L6Chock0-10-A11"  
/sex="M"  
/cell\_line="Cho-CR"  
/lab\_host="Top10F"  
/clone\_jib="L6Chock0"  
/note="Organ: Liver; Vector: pcNS-D2; Site\_1: EcoRI;  
Site\_2: NotI; The poly (A)+ RNA was dephosphorylated with  
bacterial alkaline phosphatase (BAP) and then dephosphorylated  
with tobacco acid pyrophosphatase (TAP). The dephosphorylated  
intact mRNA was ligated with DNA-RNA linker including  
EcoRI site by treatment of T4 RNA ligase and the first  
strand cDNA was synthesized from oligo dt-selected mRNA by  
priming with dt-tailed vector. The dt-tailed vector was

adjusted to have about 60nt. The cDNA vector was circularized with E. coli DNA ligase after digestion of EcoRI which site is also included in vector. An RNA strand converted to a DNA strand by Okayama-Berg method. The obtained cDNA vectors were used for transformation of competent cells E. coli Top10F by electroporation method. The cDNA libraries constructed by this method are full-length enriched cDNA library."

## ORIGIN

Query Match 98.8%; Score 212.4; DB 6; Length 356;  
Best Local Similarity 99.5%; Pred. No. 1.7e-50;  
Matches 213; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 ATAAAGGCTAGAGGCTGCTGCGACAGTCCACTCTTTTCAGAGTGAATCCC 60  
DB 1 ATAAAGGCTAGAGGCTGCTGCGACAGTCCACTCTTTTCAGAGTGAATCCC 60  
QY 61 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGACGACCGGCGCTGAGTTT 120  
DB 61 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGACGACCGGCGCTGAGTTT 120  
QY 121 CCGGCGTCGGAAGAGACCGAGCTTCTTCGCGGATCCAGTTCGTTCCAGCCCCCA 180  
DB 121 CCGGCGTCGGAAGAGACCGAGCTTCTTCGCGGATCCAGTTCGTTCCAGCCCCCA 180  
QY 181 TCTCAGAGCCGACCGACAGAGAGGAGGAAACCG 214  
DB 181 TCTCAGAGCCGACCGACAGAGAGGAGGAAACCG 214

RESULT 14  
BO639435 493 bp mRNA linear EST 15-JUL-2002  
LOCUS he1se11.y1 Human Retina cDNA (Un-normalized, unamplified): hd/he  
DEFINITION Homo sapiens cDNA clone he1se11 5', mRNA sequence.  
ACCESSION BO639435  
VERSION BO639435.1 GI:21763894  
KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
1 (bases 1 to 493)  
Wistow, G., Bernstein, S.L., Wyatt, M.K., Ray, S., Behal, A.,  
Touchman, J.W., Bouffard, G., Smith, D. and Peterson, K.

Expressed sequence tag analysis of human retina for the NEIBank  
Project: Retbindin, an abundant, novel retinal cDNA and alternative  
splicing of other retina-preferred gene transcripts  
Mol. Vis. 8 (4), 196-204 (2002)

TITLE Contact: Wistow G  
JOURNAL Section on Molecular Structure and Function  
MEDLINE National Eye Institute  
PUBMED 6/331, NIH, Bethesda, MD 20892-2740, USA  
Tel: 301 402 3452  
Fax: 301 496 0078  
Email: greene@helix.nih.gov  
Plate: 15 row: e column: 11  
Seq primer: M3RPI reverse primer (AB1).  
Location/Qualifiers  
1..493

## FEATURES

source  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="he1se11"  
/cissue="Retina"  
/dev\_stage="Adult"  
/lab\_host="EMD108"  
/clone\_lib="Human Retina cDNA (Un-normalized,  
unamplified): hd/he"  
/note="Organ: Eye; Vector: pSPORT1; Neural retina tissue

was dissected from two 80 year old donors with no observed  
eye disease. 100ug of total RNA was used for library  
construction. A directionally cloned cDNA library in the  
pSPORT1 vector (Life Technologies) was constructed at  
Bioserve Biotechnology (Laurel MD) essentially following  
the protocols of the SuperScript Plasmid System full  
details of which are contained in the manufacturer's  
instruction manual (<http://www.lifetech.com/>). First  
strand synthesis was carried out using a Not I  
primer-adaptor  
15'-pGATTAATTCTAGATCCGAGCGGCGCCCT(T)15-3'. EST analysis  
was performed on the unamplified library at the NIH  
Intramural Sequencing Center (NISC)."

## ORIGIN

Query Match 98.8%; Score 212.4; DB 5; Length 493;  
Best Local Similarity 99.5%; Pred. No. 1.8e-50;  
Matches 213; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 ATAAAGGCTAGAGGCTGCTGCGACAGTCCACTCTTTTCAGAGTGAATCCC 60  
DB 10 ATAAAGGCTAGAGGCTGCTGCGACAGTCCACTCTTTTCAGAGTGAATCCC 69  
QY 61 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGACGACCGGCGCTGAGTTT 120  
DB 70 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGACGACCGGCGCTGAGTTT 129  
QY 121 CCGGCGTCGGAAGAGACCGAGCTTCTTCGCGGATCCAGTTCGTTCCAGCCCCCA 180  
DB 130 CCGGCGTCGGAAGAGACCGAGCTTCTTCGCGGATCCAGTTCGTTCCAGCCCCCA 189  
QY 181 TCTCAGAGCCGACCGACAGAGAGGAGGAAACCG 214  
DB 190 TCTCAGAGCCGACCGACAGAGAGGAGGAAACCG 223

RESULT 15  
CB154948 511 bp mRNA linear EST 29-JAN-2003  
LOCUS K-EST0213039 B2N807043 Homo sapiens cDNA clone B2N807043-30-G11 5',  
DEFINITION mRNA sequence.  
ACCESSION CB154948  
VERSION CB154948.1 GI:28140051  
KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
1 (bases 1 to 511)  
Kim, N.S., Hahn, Y., Oh, J.H., Lee, J.Y., Ahn, H.Y., Chu, M.Y., Kim, M.R.,  
Oh, K.J., Cheong, J.E., Sohn, H.Y., Kim, J.M., Park, H.S., Kim, S. and  
Kim, Y.S.

TITLE 21C Frontier Korean EST Project 2001  
JOURNAL Unpublished (2002)  
COMMENT Contact: Kim YS  
Genome Research Center  
Korea Research Institute of Bioscience & Biotechnology  
52 Boeun-dong Yuseong-gu, Daejeon 305-333, South Korea  
Tel: +82-42-860-4470  
Fax: +82-42-860-4409  
Email: yongsung@mail.kribb.re.kr  
Plate: 30 row: G column: 11  
High quality sequence stop: 511.  
Location/Qualifiers  
1..511

## FEATURES

source  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="B2N807043-30-G11"  
/sex="M"  
/lab\_host="Top10F"  
/clone\_lib="B2N807043"  
/note="Organ: Brain; Vector: pCNS-D2; Site 1: EcoRI;

Site\_2: NotI; The poly (A) + RNA was dephosphorylated with bacterial alkaline phosphatase (BAP) and then decapped with tobacco acid pyrophosphatase (TAP). The decapped intact RNA was ligated with DNA-RNA linker including EcoRI site by treatment of T4 RNA ligase and the first strand cDNA was synthesized from oligo dt-selected mRNA by priming with dt-tailed vector. The dt-tailed vector was adjusted to have about 60nt. The cDNA vector was circularized with E. coli DNA ligase after digestion of EcoRI which site is also included in vector. An RNA strand converted to a DNA strand by Okayama-Berg method. The obtained cDNA vectors were used for transformation of competent cells E. coli Top10F' by electroporation method. The cDNA libraries constructed by this method are full-length enriched cDNA library."

# ORIGIN

```

Query Match      98.8%; Score 212.4; DB 6; Length 511;
Best Local Similarity 99.5%; Pred. No. 1.8e-50;
Matches 213; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1  ATACGGCTAGGCTGAGAGAGTGTGCGACAGTCCACTCTTTTCGAGAGTGACTCCC 60
Db      1  ATACGGCTAGGCTGAGAGAGTGTGCGACAGTCCACTCTTTTCGAGAGTGACTCCC 60

Qy      61 GTTGTCCCAAGGCTTCCAGACGAACTGTGCGGCTGCGAGCACCGGCGCTCGAGTTT 120
Db      61 GTTGTCCCAAGGCTTCCAGACGAACTGTGCGGCTGCGAGCACCGGCGCTCGAGTTT 120

Qy      121 CCGGGGTCCGGAAGACCGAGCTTTCTGCGGATTCAGTTCGCTTCCAGCCCCCMA 180
Db      121 CCGGGGTCCGGAAGACCGAGCTTTCTGCGGATTCAGTTCGCTTCCAGCCCCCMA 180

Qy      181 TCTCAGAGCCGACGACGACGAGAGAGGGAACCG 214
Db      181 TCTCAGAGCCGACGACGACGAGAGAGGGAACCG 214
  
```

Search completed: February 11, 2005, 09:02:43  
 Job time : 1646 secs